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1. Introduction 
“When health is absent, wisdom cannot reveal itself, art cannot manifest, strength 
cannot fight, wealth becomes useless, and intelligence cannot be applied.” 
- Herophilus (335-280 BC), Greek physician 
1.1. Diagnostics and healthcare 
Global demographics estimate the population of the world to be 7 billion [1] with an 
average life expectancy at birth as reported by the WHO for 2011 at 70 years. The World 
Health Organization (WHO) also reports that the life expectancy after 60 years to be an 
additional 20 years on the average [2]. This milestone achieved by the world in its 
population puts added pressure on healthcare budgets worldwide. As people live longer 
and die at lower rates, the number of years spent living with a chronic disease, non-
communicable diseases or disabilities such as back pain has risen. To address the 
burden of global health expenditure the healthcare system needs to be put under 
scrutiny.   
  To date, modern medicine has focused on the development and delivery of 
therapeutic interventions and the value of diagnostics has yet to be fully tapped into. 
Diagnostics tools can help improve the evaluation and efficiency of disease treatment. 
They are also valuable for identifying the presence and cause of disease and for 
determining an appropriate course of treatment. Though diagnostics comprises only 3-
5% of the healthcare spending, it impacts 70% of medical decisions [3] and supports 
correct identification in over 50%  of diseases [4, 5]. Some of the benefits provided by 
accurate diagnosis include [6-8]: 
• The unnecessary treatment of patients is avoided 
• Circumvention of any harmful side effects due to redundant therapy 
• Fewer drug resistant pathogens due to needless use of broad band antibiotics 
The need for diagnostics is hence being met by various purpose-built centralized 
laboratories that have mushroomed. In the U.S. at present, there are 240,000 [9] 
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registered laboratories which must meet the demands of its growing population, ranked 
as the third most populous country in the world at 0.3 Billion [10]. Some of the features of 
such consolidated testing facilities include [11]: 
• Batch processing of large sample volumes 
• The possibility of complex and multiple analytic investigations 
• Reliable and robust results 
• Quality management 
A common obstacle faced by centralized laboratories in catering to the diagnostic 
needs of society, is in the access itself. As testing takes place in consolidated central 
laboratories specimens collected at the doctor’s office or local clinics must be preserved 
and shipped under cold chain (Figure 1.1.1) to the testing facility. This leads to longer 
turnaround times and added costs due to logistics apart from the usual incurred labor 
and machine costs. 
 
Figure 1.1.1 Biospecimens are collected at point-of-care, preserved and shipped using a 
cold chain to a central laboratory that processes samples at high throughput. The results 
are then communicated to the healthcare giver and necessary action is taken (Redrawn 
from  [12]). 
 
Localized laboratory analysis can thus streamline this process with new 
emerging technologies to complement the system. For example, easy-to-use tools 
providing rapid diagnosis can allow therapy to start sooner. Accordingly, the 
commercialization of compact and portable diagnostic devices is aimed towards 
allowing fast and easy access to laboratory testing. The term coined for this testing 
taking place at the patient’s site in say local clinics or the doctor’s office is called point-
of-care testing (POCT)[5]. 
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1.1.1. In-vitro diagnostic market 
Growing in-vitro markets bringing more investors [13] reflects the increasing 
demand for diagnostic testing [14]. The aging population of developed nations and 
growing needs of developing countries has spurred this interest in laboratory testing.  
In-vitro diagnostics (IVD) are categorized under medical devices and thus require 
the approval of the Food and Drug Association (FDA) [15, 16] in the U.S. and of the 
European Medicines Agency (EMA) in Europe. The IVD segment includes reagents, 
diagnostic testing products, instrumentations and other related products applied in both 
clinical and research laboratories. The aim of IVD testing is to identify causes of disease 
by the testing of bodily fluids (blood, urine, sputum) or tissue samples and is thus not 
based exclusively on syndromic management of infection [17].  
The medical device market in 2011 for U.S. was $109 billion with a world share of 
41% and growth of 4%. Europe coming in second had a market share of $95.5 billion, 
world shares of 36% with growths of 6% [18]. The IVD market has also been growing at a 
steady 4-6% [19] with world markets growing from $28.5 billion in 2004 [20] to an 
estimated $60 billion in 2015 [21]. The largest sector in terms of market value share in 
year 2010 was in professional diagnostic testing which includes clinical chemistry, 
immunoassays, point-of-care (POC) and microbiology tests. Other segments include 
diabetes monitoring, tissue and molecular diagnostics (Figure 1.1.2), with trends not 
having changed much since 2004 [3, 13, 17, 18, 20-22].  
 
Figure 1.1.2 In-vitro diagnostics showing sales in the various sectors (Redrawn from [21]). 
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Thus, clinical pathology where testing of bodily fluids is undertaken remains the 
largest sector. The diagnostics market is dominated by a handful of multinational 
companies presented in Table 1.1.1, where around 10 leading companies account for 
almost 80% of IVD sales worldwide [21, 22]. 
Table 1.1.1 The 10 leading international companies dominating 80% of the IVD market in 
years 2007 and 2010 (Reproduced from [21, 22]).  
Rank  
2007 
Company Net sales 
($ billion) 
Rank  
2010 
Company Net sales  
($ billion) 
1 Roche Diagnostics 
(CH) 
8.32 1 Roche Diagnostics 
(CH) 
9.996 
2 Siemens Medical 
(DE) 
4.72 2 Siemens Medical 
(DE) 
4.865 
3 Johnson & 
Johnson (US) 
4.1 3 Abbott (US) 3.794 
4 Abbott (US) 3.16 4 Beckman Coulter 
(US) 
3.663 
5 Beckman Coulter 
(US) 
2.163 5 Thermo Fisher (US) 2.374 
6 BD (US) 1.905 6 Becton Dickinson 
(US) 
2.319 
7 BioMerieux (FR) 1.564 7 Johnson & Johnson 
(US) 
2.053 
8 BioRad (US) 0.832 8 BioMerieux (FR) 1.8 
9 Sysmex corp (JP) 0.792 9 Alere (US) 1.536 
10 Unkown  10 Sysmex corp (JP) 1.422 
 
1.1.2. Microfluidics in Point-of-Care Testing 
Central laboratory testing, though at present cheaper than POCT per test  suffers 
from the following disadvantages [19, 23]: 
• Slower sample to answer times 
• Longer hospital stays 
• More labor steps due to logistics involved 
• No possibility for home monitoring 
Therefore, POC tests are important where results are needed rapidly (e.g. emergency 
rooms or ambulances and on weekends), where laboratory facilities are not provided 
(e.g. military or forensic functions) and in low resource settings (e.g. in developing 
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countries) [24]. Therefore, many diagnostic companies believe in the potential of simple, 
rapid POCT platforms. The POC market is predicted to reach $38 billion by the year 2017 
which is about 16% of the global IVD market [24]. The attention received by POCT is in 
part due to the emergence of new enabling technologies such as information technology, 
molecular diagnostics, nanotechnology and microfluidics just to name a few [19]. 
Microfluidics in particular is a suitable technology  for the POC applications and is 
growing rapidly [25]. The microfluidic technology contribution to the IVD market of $57 
billion in 2012 was $787 million [18] and is predicted to grow to $16 billion in 2017 [24] 
with a number of start-ups in addition to established diagnostic companies [18, 22, 26]. 
Functionalities that make microfluidics attractive to the diagnostic branch include [27]: 
• Use of nL to µL of sample and reagent volumes leads to reduced costs 
• Miniaturization and integration lead to portable devices 
• Automation of protocols possible for complex laboratory testing 
• Increased detection sensitivities possible due to the small volumes 
• Faster processing speeds allow quick sample to answer times 
• Disposable and single use devices 
• Lower power consumption 
The name coined for these microfluidic devices coupled to sensors for analysis in 
medical, environmental and life sciences is Lab on a Chip (LOC) system.  
Features for microdevices for POC application depend upon the site of application 
(home, doctor’s office or emergency room) and the resource settings with developed 
countries being able to pay more per test. While non-communicable diseases such as 
cardiovascular diseases, diabetes, cancer etc. are some of the major health issues in 
developed countries, the developing world is coping with the burden of communicable 
infectious diseases (HIV, Hepatitis B/C, Tuberculosis etc) [28-30]. Furthermore, developed 
nations have established utilities (electricity, clean water) and often cater to needs of 
less population. Accordingly the ASSURED (A-Affordable; S-Sensitive; S-Specific; U-User-
friendly; R-Robust and rapid; E- Equipment-free or minimal and D- Deliverable to those 
who need them) acronym has been coined for the requirements to be fulfilled by a rapid 
test [28] . Companies and engineers must consider all these factors carefully when 
interested in developing LOC devices [7, 31, 32]. Just as there are many diseases 
encountered, there are many analytical methods to detect them. Some analytical 
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methods that are often seen in commercially available microfluidic diagnostic systems 
are given in Table 1.1.2 [26]. 
Table 1.1.2 Examples of commercially available microfluidic based tests with their 
applications (Adapted partly from [26, 30]). 
Application Examples Concentration 
range 
Detection  examples 
Blood 
Chemistries 
Metabolites, 
lipids, 
electrolytes, 
gases 
µM-mM Electrochemical  detection of 
immunoenzymometric 
assay (iSTAT® Abbott) [33] 
Absorption measurement based on 
enzyme reactions (Piccolo® xpress, 
Abaxis Inc.) [34] 
Biomarkers Cardiac markers, 
proteins 
fM-nM Fluorescence immunoassay 
(Triage® System, Alere Inc.) 
Frustrated total internal reflection 
of magnetic beads 
(Magnotech™,Philips) [35] 
DNA, RNA Pathogen 
detection 
aM Fluorescence detection of PCR 
products (GeneXpert® , Cepheid) 
(Simplexa™,Focus Diagnostics Inc.) 
Whole cells CD4+ T-Cell 10 cells/µL-1000 
cells/µL 
Fluorescent detection antigen-
antibody based (Alere PIMA™ CD4, 
Alere Inc.)  
Flow cytometry (CyFlow®miniPOC, 
Partec GmbH) [36] 
 
For a more detailed list of companies working on microfluidic POCT systems, please 
refer to Chin, C. D. et. al [26]. The detection of biomarkers and pathogens, either 
immunoassays or polymerase chain reaction (PCR) based assays are being employed, as 
seen in Table 1.1.2. 
 PCR is recognized as one of the most important discoveries of the last century and 
has quickly become an important biochemical technique. It is used to amplify nucleic 
acids (DNA and RNA) using a three phase cyclic process – denaturing, primer annealing, 
extension of DNA strand. Firstly, the targeted DNA is denatured by heating it, then the 
primers for their complements are annealed to the two parts and finally polymerase 
enzyme is used to extend them, to give the complementary nucleotides (Figure 1.1.3). 
Thus, after n cycles one ends up with 2n copies of the original DNA [37]. 
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Figure 1.1.3 Schematic of classical PCR performed on the double stranded DNA. 
 
The PCR method though highly sensitive and specific also suffers from disadvantages 
such as [38]: 
• Cross contaminations 
• Labor intensive 
• Requiring expensive reagents and laboratory equipment 
• Skilled personnel needed to perform tests 
The PCR method is of particular interest as a diagnostic tool for pathogen detection. 
Present in trace quantities, which are often enough to cause an infection, pathogen 
detection is a challenge. Larger sample volumes in milliliters are often needed to have 
enough target analyte material to begin. However, these large clinical volumes are 
difficult to interface with usual microfluidic volumes in µL to pL. Although, the complex 
nature of the procedure calls for a more complicated chip design various microfluidic 
platforms capable of performing PCR have emerged [39-42] as well as newer PCR 
techniques such as Loop-mediated isothermal amplification (LAMP) [43]. Carrying out 
PCR on a LOC system would call for many added steps apart from the nucleic acid 
amplification and labeling for the final readout such as sample pre-treatment-cell 
sorting, isolation, lysis. Moreover, the complete integration remains a difficulty and 
many researchers continue to search for other easier methods. Thus, nucleic acid based 
tests fulfilling the ASSURED criteria are yet to be commercialized [44]. 
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Recently, immunoassays are increasingly being transferred onto microfluidic-based 
systems [45-51]. Immunoassays since their establishments in the 1950s [49] have 
developed into an important protein analysis method in the diagnostic market. They 
demonstrate various advantages such as specificity and selectivity towards a target as 
well as are relatively simple to implement (see section 3.3 for more details). 
Furthermore, the discovery of new specific biomarkers [52-54] for early onset of diseases 
can be diagnosed using an immunoassay format example: diseases of the heart [55, 56] and 
cancer [57, 58]. Immunoassays have been employed in lab based tests for the detection of 
[17]: 
• Infectious diseases 
• Tumor markers 
• Cardiac markers 
• Diabetes 
• Thyroid 
• Proteins 
• Autoimmune diseases 
• Anemia 
• Therapeutic drugs or drugs of abuse 
• Fertility 
• Allergy 
Most commercially available immunodiagnostic tests employing microfluidics to 
date are lateral flow assays. Lateral flow assays (LFA) are composed of a carrier 
material such as nitrocellulose membrane onto which assay reagents are dried and 
stored. Upon application of a few drops of sample fluid, the reagents are rehydrated 
and the immunochemical reaction takes place as in Figure 1.1.4 [59]. 
 
Figure 1.1.4 Schematic illustration of a lateral flow assay (Redrawn from [59]).  
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The fluid moves through the porous membrane through capillary action or wicking. The 
readout is often due to visual inspection of a color change, though many times a reader 
is provided for quantification. Thus, lateral flow assays are based on a simple principle 
and are cheap and easy to use. They are however limited to producing qualitative, or 
semi-quantitative  read-outs [60]. Despite their commercial success, these products 
cannot mirror the multi-step procedures of laboratory testing [46].  
1.2. Objectives 
Upon surveying the microfluidic based POC assays (Table 1.1.2) one observes that 
there is room for a platform for more complex assay formats which cannot be offered by 
LFAs. Though Polymerase Chain Reaction (PCR) has gained much popularity it suffers 
from disadvantages as mentioned in section 1.1.2. Moreover, its integration into a device 
keeping with requirements mentioned above make it unfavorable. Furthermore, PCR 
detects the amplified genetic makeup nucleic acid, such as DNA, to make it easier to be 
detected. Accordingly, a concept was proposed entailing antibody loaded beads to allow 
the quantitative binding of antigen particles. Immunoassays can additionally be adapted 
ideally onto a microfluidic based POC systems. However, they are not as sensitive as PCR 
based methods and aiming to improve their sensitivities was in part a goal in this thesis. 
Microfluidics would allow improvement in sensitivity to an extent but choices made 
right from the assay design can affect the ultimate detection limit.  
An ideal solution would allow individual assay steps to be adapted and would 
provide a sample-to-answer system, being both quantitative as well as sensitive. An 
integrated system which should be able to perform sample preparation and extraction of 
targets on chip. The method should not be limited by the size of the sample volume, also 
allowing probing of more than a fingerpick of blood (> 20 µL). This would permit the 
detection of even very low concentrations of diagnostic targets such as pathogens or 
rare cell types. The focus on POCT would require the device to be fully self-contained, 
disposable and amenable to being operated by untrained users. The disposables such as 
the chip should be manufactured cost-effectively within a few production steps and not 
comprise many pick and place elements.  
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The hypothesis for this thesis was: 
It is possible by precise manipulation of functionalized particles in a microfluidic cartridge, 
to reach a limit of detection (LOD) similar to that of Polymerase Chain Reaction which is to 
have a sensitivity of <103 Particles/mL hence achieving detection of viral antigens, rare 
cells types and other biological particles in clinical samples. 
The hypothesis can be broken down into three main aims namely: 
• Microfluidic POC system 
• Manipulation of antibody loaded particles in system 
• Quantitative and sensitive detection of antigens 
Considering all these requirements research and development into various 
aspects such as the chip with its manufacturability, assay scheme and actuation on chip, 
detection methods and improving overall sensitivity, was started. 
Firstly, the functional microfluidic blocks with optimal properties for an assay 
process were considered. The result aimed for would be a functional prototype allowing 
sample preparation, incubation, washing, labelling with detection antibody and final 
detection. The material itself governing the costs and production steps, with injection 
moulding of polymer being cheaper in comparison to etching of glass. Adhesion 
technology such as double-side coated tape, adhesives etc. for the bonding of chip 
components to form an impervious seal depending upon the substrate choice. The final 
method must be in accordance to overall design, ease of manufacturing and intended 
use. Design of valves for fluid control, passive or active mixing structures, chamber 
shapes for bubble-free filling and channels were scrutinized. 
Research was executed into various beads as assay solid phase considering points 
such as polymer or polymer matrix with a magnetic core, diameter and surface 
properties. This would be chosen in accordance with the final actuation scheme – 
magnetic, acoustic waves, electrokinetic phenomena. Magnetic beads would allow ease 
of manipulation but are opaque where as silica or polymer beads lead to more 
complicated handling. For a magnetic actuation, research was undertaken into assay 
steps using beads such as micromixing with beads arranged into pearl chains and final 
aggregate formation by magnetic concentration. For the actuation aspects considered 
included magnet type and mounting, magnetic shielding if required, parameters for 
manipulation and control of particles and the prevention of severe aggregation. The final 
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periphery for the prototype cartridge should to be compact and portable. Possible 
detection schemes to be considered included confocal fluorescence detection or 
electrochemical detection and corresponding electrode design. 
1.3. Strategy 
Presented in this thesis is an original method, involving an injection-molded 
polymer cartridge, capable of emulating the functionality offered by large laboratory 
immunodiagnostic instruments. The cartridge (Chapter 4) comprises of various 
chambers, which are individually filled with the required assay reagents. Various 
microfluidic features are included such as passive stop valves [61-63] and phaseguides [64, 
65] for controlling the fluid. The cartridge was conceptualized to be produced by a single 
and cost-effective manufacturing step, involving microinjection molding bestowing it 
with every microfluidic function required.  
Magnetic beads form the solid phase, which can be manipulated in the chambers 
through magnetic actuation via an externally applied magnetic field (Chapter 5). This 
would eliminate the need for pumps and tubing or a centrifuge, typically needed for fluid 
handling and enables touch-less operation of the assay within the cartridge. The 
magnetic beads can also be used for active incubation with the sample by assembling 
them into pearl chain microstirrers [66]. During active incubation, the microstirrers scan 
the entire sample volume systematically to extract targets. This format can also address 
larger sample volumes without being limited by sample size.  
The device and method allows for mixing (incubation, washing), reagent 
exchange needed in immunoassays and detection. These characteristic ensure a fully-
automated, self-contained universal immunoassay platform. In Chapter 6&7 two assays 
that were used to evaluate the system are presented. The described work could thus be 
a potentially valuable tool for disease monitoring and follow-up, especially since the 
strategy offers the advantages of microfluidics as well as meets the requirements for 
POC analysis. 
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2. State of the Art 
During the design of the platform (cartridge and periphery), there were a number of 
technological options to choose and develop on. The microfluidic tool kit is extensive 
with numerous methods to achieve the tasks needed to automate an immunoassay, as: 
• Pumping and valuing of various reagents 
• Mixing and metering of the liquids 
• Sample preparation of test fluid  
• Separation of analyte 
An important feature desired in a diagnostic tool is that of sample preparation and 
an attractive way to incorporate this on chip is using magnetic beads.  
Magnetic beads first invented in the 1970s have presented many advantages in 
biological studies and biomedical applications including microfluidics [67-69]. They are 
used in microfluidics for isolation or separation of cells and proteins [70-72], in 
immunoassays [73, 74], for sorting of cells [75] and also as a label [67, 76] . Some of the 
benefits offered by magnetic beads include [77]: 
• They are cheap and readily available in different sizes 
• They come with various surface chemistries for immobilizing various 
biomolecules 
• They offer control over process steps 
• The magnetic forces do not interfere with biological samples 
• Magnetic forces are not affected by the temperature, pH, surface charges or ionic 
concentrations of the sample fluid 
Magnetic beads can be used for mixing as well as for separation and sample 
preparation. Using a magnetic bead based assay would also circumvent the need for 
pumps needed for the delivery of reagent. Thus, magnetic beads with an actuation 
scheme were exploited in this work to serve many of the above listed requirements.  
In magnetic actuation schemes previously investigated by other research groups 
[78, 79], magnetic beads were used for separation [80-84] or mixing [85-89] but were not 
exploited for the integration of a complete assay procedure.  
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2.1. Magnetic beads for mixing 
Rapid mixing is often a problem in microfluidic systems due to laminar flow 
regimes that dominate at the microscale. Magnetic beads manipulated by a rotating 
magnetic field provide a simple and effective active mixing method that can be employed 
in continuous flow or stationary systems. 
Suzuki, H. et al. 2004 [90] used micro conductors to mixing streams of  biological 
fluid and magnetic beads suspensions in a serpentine microfluidic channel, due to locally 
created magnetic fields. They were also able to attract the magnetic beads upon applying 
current to a pair of the microconductors.  
Rida, A. et al. 2003 [91] created a alternating magnetic field to create wobbling 
magnetic aggregates and enhanced mixing by 95% at flows of 0.5 cm/s. Thus, they were 
able to control the porosity of the magnetic bead aggregate solely depending upon the 
magnetic field and flow rate. 
Lee, S.H. et al. 2009 [85] reported mixing using ferromagnetic particles assembled 
into rod-like structures. Mixing was enhanced when the rod-like structures formed large 
aggregates and they achieved a final mixing efficiency of 96% at a flow rates of 1.2-4.8 
mm/s. This was quantified by fluorescence intensity profile taken over the mixing 
distance.  
The M.A. Hayes group studied the formation of magnetic beads assembled into 
stirrers by a rotating permanent magnet [66, 92, 93]. They used this system for performing 
immunoassays [78, 79] and reported improved detection sensitivities due to i) increase of 
mass transport due to mixing ii) higher signal to noise rations due to frequency and 
phase filtering (lock-in amplification) detection method. 
In a stationary or stop flow system Herrmann, M. [86, 94] used magnetic bead plugs 
rather than stirrers to mix and perform an Enzyme-Linked Immuno-Sorbent Assay 
(ELISA). They made use of a single chamber for the entire assay and would require 
pumps for the final platform. 
Rotating superparamagnetic particles have also been used to increase enzyme 
activity [95] and PCR product efficiency [96] due to increased probability of collision with 
non-reacted reagent. These reports demonstrated how the rotational frequency of the 
magnetic microstirrers effects not only the shape, size and dynamics of the chains going 
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from chains through clusters to discs upon increasing the frequency. Furthermore, 
Mikzuki, T. et al. 2010 [95] showed optimal enzyme activity at rotational frequencies 
below 5Hz. 
Wittbracht, F. et al. 2012 [97] used a combination of rotating magnetic fields to mix 
and a geometrical separation to separate magnetic agglomerates. Mixing has also been 
performed by a stationary magnetic field and a rotating capillary tube containing 
superparamagnetic particles [98]. 
The group of  J.M.J. den Toonder are experimenting with magnetic beads in a fluid 
cell to study the mass transport [99] occurring to the microparticle surface upon varying 
their topologies. The magnetic chains are actuated by a rotating magnetic field produced 
by an octopolar electromagnetic system. Furthermore, they were able to use the 
electromagnetic system for the disaggregation of the bead clusters. [89, 100]. 
More recently  Tekin, H.C. et al. 2013 [101] have achieved attomolar detection of 
Tumor Necrosis Factor-a (TNF-a) from 5µL of serum using larger magnetic beads bind 
target and smaller beads as a label. 
From literature one can conclude that magnetic beads assembled into 
microstirrers provide efficient and through mixing in laminar microfluidic devices. They 
lead to enhanced signals recorded and in certain reports can be exploited for the read-
out as well. The microstirrers are simple to implement and their length can be 
controlled based on the rotation frequencies. 
2.2. Magnetic beads for reagent exchange 
Magnetic microbeads for the immobilization of antibodies against targeted antigen 
can serve numerous functions. One such function can be for the exchange of reagents 
needed during an immunoassay. As magnetic beads can be manipulated easily, they can 
be moved to various areas on a microchip (chambers) containing different buffers. 
Several groups work with magnetic beads moving between fluid containing chambers to 
bind targets and thus carry out an assay. 
 In particular, Chen et al. 2011 [83] and Berry et al. 2012 [102] demonstrated a 
Polydimethylsiloxane (PDMS) and glass based chip using oil to separate cavities through 
which magnetic beads were transported. However, dragging the beads through an oil 
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phase may lead to a film of oil coating the beads, which later on may be difficult to 
remove. The procedure requires twice as many pipetting steps for loading both the 
buffers and the oil phase needed for an assay. Thus, the effective reagent loading time is 
longer and making automation more complicated. Moreover, oil undergoes expansion 
and shrinking depending on ambient temperature thus leading to changes in volume of 
the buffer pockets. 
Various droplet-based systems also make use of magnetic beads for reagent 
exchange. These systems also require an oil phase to create the droplet and sustain their 
form due to surface tension effects. Lehmann, U. et al. 2006 [103] made use of coils on a 
printed circuit board (PCB) instead of moving a permanent magnet for the actuation of 
the beads. The system is channel-less and was used to extract DNA for cell debris, the 
PCR amplification was however undertaken off chip.  
 Shikida, M. et al. 2006 [81] reported a chip consisting of a glass plate patterned with 
hydrophobic and hydrophilic regions and a rubber sample well assembly. The various 
buffers and magnetic beads where deposited in these sample wells with oil separating 
them. The beads were moved via an externally place permanent magnet thus performing 
a complete ELISA on chip.  
Gu, S-Q et al. 2011[104] performed a novel manipulation of picoliter droplets by using 
magnetic beads for extraction of DNA and ferromagnetic microparticles as tiny magnets. 
The DNA coupled to the magnetic beads were moved using the magnetized 
ferromagnetic particles magnetization through an external magnet, between reagent 
filled droplets. 
Work using droplets without oil has been reported by Zhang, Y. et al. 2011 [105] 
where magnetic beads were moved by a permanent magnetic between the drops. The 
pinching off of the beads from reagent reservoirs was assisted by three dimensional slits 
through which only the beads could pass.  
Other oil free developments reported include den Dulk et al. 2013 [82] involving 
special coatings on glass and where the various buffers were separated by air gaps. For 
transferring beads between buffer plugs a large number of beads were required as well 
as a very strong magnetic field. Pulling the beads between the buffer lead to losses 
incurred during the transfer. Becker, H. et al. [106, 107] and Sandetskaya, N. et al. 2011 [108] 
using a polymer chip where again beads were transferred between compartments. Den 
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Dulk et al. perfomed DNA enrichment on their device whereas Becker, H et al. and 
Sandetskaya, N. et al. performed PCR and isolated E.coli.  
Research undertaken using continuous flow and magnetic beads need pumps to 
create the continual stream of magnetic particles and effective incubation times with 
various buffers are shorter. Bronzeau, S. et al. 2008 [109] performed several assays 
simultaneously by flushing a sample solution over numerous plugs of magnetic beads 
with different surface coatings. Whereas Peyman S.A. et al. 2009 [110] introduced beads 
on one side of a microfluidic chamber which are then deflected towards the permanent 
magnet on the opposite side. During this deflection, beads travel across parallel reagents 
streams in which several binding and washing steps for a sandwich immunoassay were 
performed. Karle, M. et al. 2010 [111] deflected beads between different flowing streams 
using a rotating magnet which they called phase-transfer magnetophoresis. DNA 
extraction from E.coli lysate was performed. 
Numerous centrifugal microfluidic platforms using magnetic beads also exist, the 
function of the beads is for separation or transport [112-114]. These platforms thus make 
use of a centrifuge principle for fluidic control and mixing, where fluid moves from the 
inner to outer edge of a spinning disc. 
Research involving a stationary fluid phase with a mobile solid phase, has been 
undertaken by various groups. However, these groups work principally with plugs of 
magnetic beads, which can lead to limited sensitivities. This is due to the high density of 
beads aggregated to form the plug leading to relatively poor perfusability thus 
decreasing interaction with targets in sample. Lacharme, F. et al. [115, 116] showed how 
chains of magnetic beads allowed optimal interaction with targets during a sandwich 
immunoassay. By combining, the advantages offered by the magnetic beads themselves 
with an actuation scheme for mixing and transferring the beads between reagent 
compartments one ends up with a system with high functionality (Table 2.2.1). 
Table 2.2.1 Advantages and disadvantages offered by different actuation schemes. 
Magnetic stirrers Magnetic plugs 
+ Active mixing 
+ Increased mass transport 
+ Transfer between reagent chambers 
+ Pumping reagents circumvented 
- Reagents pumped into a single chamber - Poor plug perfusability  
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3. Theory 
3.1. Microfluidics and fluid behavior 
Microfluidics deals with the miniaturization of geometries used to confine small 
volumes of fluid (µL, nL, pL, fL). This downscaling leads to a high surface to volume ratio 
and allows control and manipulation over the fluid behavior making it more predictable. 
The change in fluid flow occurs because volume forces such as gravity and inertia exert 
little effect as compared to surface forces like surface tension and viscosity. This is 
explained best by considering the scaling laws for the ratios of these two classes of 
forces as follows: 
2
3 →→∞
Surface  Forces L -1= = L
Volume   Forces L
L 0  
 
(3.1-1) 
 
This law hence illustrates that when scaling down, the volume forces known to us 
are negligible but the surface forces change the rules in a dramatic way. Microfluidics 
has found numerous applications since its inception in the 1980s for inkjet print heads 
DNA chips, lab-on-a-chip technology, micro-propulsion, and micro-thermal 
technologies[117]. 
3.1.1.  Interfacial physics 
As described above miniaturization leads to a dominance of surface forces in 
microfluidic systems. To understand their effect on the system behavior it is necessary 
to study the Gibb’s free energy G. The surface tension of an interface is defined as the 
Gibbs free energy per area for fixed pressure and temperature. Another interfacial force, 
which results from the interaction of liquid, gas and solid surfaces, is the capillary force. 
Cohesive forces between molecules, which are balanced in the bulk of the liquid, are 
weaker at the interface of the liquid and gas. As a result, the liquid molecules at the 
interface experience net force acting inward as in Figure 3.1.1. The overall effect is a 
decrease in free surface of the liquid exposed to the gas, say air. This decrease can also 
be by the surface tension as in equation (3.1-2). 
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Where ∂G	is the change in energy (Nm), ∂A is the change in area (m2) and  is the 
surface tension in (Nm-1). 
 
Figure 3.1.1 Molecules in the liquid experience a balance of cohesive forces where as 
molecules at the interface between a liquid and air are unbalanced cause a net inward 
force (Adapted from[118]) . 
 
 Interfaces such as between a solid, a liquid and a gas have been studied extensively. The 
Young’s equation gives a relationship between the equilibrium forces at the edge of a 
resting drop. 
 
Figure 3.1.2 Schematic for Young’s Equation for the surface and interfacial tensions of a 
resting drop. 
 
The surface and interfacial tensions is hence given by: 
cosθγγγ lsls ⋅+=  
(3.1-3) 
Where γs is the surface tensions between the solid and then saturated vapor of the 
liquid, γl is the surface tension of the drop versus the saturated vapor and γsl is the 
interfacial tension between the drop and the solid. The contact angle θ corresponds to 
the angle between the vectors γsl and γl. There are various analyzing methods available, 
which help measuring the contact angle of a liquid on solid and for determining the free 
surface energy of the solid 
[119-121]
.  
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Conic section method 
 In this model, an elliptical drop shape is assumed. The conic section method or 
tangent method fits a general conic section equation to the drop shape. The contact 
angle is determined as the angle between the baseline (solid support) and the tangent at 
the conic section curve at the three-phase contact point. Thus, angles are measured 
between the baselines and on either side left or right of the droplet. The measuring 
range includes angles between 10°-100° with droplet contour being symmetrical or 
slightly asymmetrical [122, 123]. 
The Owens, Wendt, Rabel and Kaelble method 
 
Figure 3.1.3 Contributions from various interactions, which make up the conclusive surface 
tension of a resting drop. 
 
This method [119, 120, 124] assumes that the surface energy is the combination of 
dispersion (non-polar) and polar energy [125]. The dispersion energy stems from the 
interaction of non-polar molecules and the polar energy comes from interactions with 
polar groups. Thus the disperse fraction of a substrate gives its hydrophobic character 
whereas the polar part describes the hydrophilic character [120]. The disperse fractions 
are always present regardless of the chemical nature of the system the coulomb 
interactions of polar groups include hydrogen bonding, dipole included interactions, 
acid-base interactions. Therefore, one obtains: 
p
l
d
ll γγγ +=  
p
s
d
ss γγγ +=  
(3.1-4) 
(3.1-5) 
Where dlγ  and 
p
lγ represent the disperse and polar parts of liquid 
d
sγ and 
p
sγ stand for the 
respective contributions of the solid.  
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This method is also called the geometric mean method as the interfacial energy can be 
calculated from the above given contributions forming the geometric mean. 
( )plpsdldslssl γγγγ2γγγ ⋅+⋅−+=  (3.1-6)
 
Where slγ is the interfacial surface tension expressed in terms of disperse and polar 
parts of both the solid and liquid. Upon substituting the above given terms in equation 
(3.1-3) and solving for the unknown quantities an equation for a straight line (3.1-7), as 
given in equation (3.1-8) is obtained. 
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Upon plotting y versus x one can calculate the psγ from the slope m and dsγ from the 
intersection with the vertical axis. The method entails using at least two liquids with 
polar groups in order to determine the surface energy of the sample solid [126].  
3.1.2. Passive fluid control 
In order to control fluid flow in a microsystem one can employ methods of actuation 
such as external pumps and valves. These entail active energy transfer to the fluid and 
include moving parts. However, there are other means to control the fluid without 
actuation or moving parts solely based on surface forces. This way of controlling fluid 
can be termed passive or autonomous fluid control [63, 127, 128]. As mentioned in section 
3.1.1 surface forces such as capillary forces, are critical at the microscale. Upon using 
capillary forces an interesting and important effect is the difference between advancing 
and receding angles for the same fluid in the same capillary also known as hysteresis. 
Normally the contact angle at the advancing edge of a liquid–solid interface is larger 
than the equilibrium contact angle, which in turn larger than the contact angle at the 
receding edge of the liquid–solid interface. This arises depending the roughness of 
surface, heterogeneity, its surface energy, interaction forces between liquid molecules 
apart from several other factors [129].   
  
cxmy +⋅=   With 
(3.1-7) 
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The study of these forces calls for scrutiny into the solid, liquid and gaseous interface. 
For most microfluidic applications, the gas is air and depending upon the design the air 
inside a microfluidic system needs to be replaced by a liquid. Therefore, a pressure 
needs to be applied in order to push the working liquid into say a non-wetting, 
hydrophobic microfluidic channel. The relation between surface tension and pressure is 
given by the following Laplace equation [130] [118]: 
⋅ΔP=γ C 
(3.1-9) 
Where C is the curvature of the liquid surface inside a microfluidic channel. Depending 
upon the shape of the channel the curvature can be different: 
R
2
C =  
21 R
1
R
1
C +=  
(3.1-10)
 
Where R is the curvature radius for a liquid in a circular channel and R1, R2 in a non-
circular channel.   
 
Figure 3.1.4 Cross section view of a liquid plug between two parallel plates made up of the 
same material (Redrawn from [117]). 
 
As the curvature also depends upon the contact angle of the advancing liquid meniscus 
in a microchannel, Figure 3.1.4, the Young-Laplace pressure drop can be given by: 
= ⋅
cos θ
ΔP γ
a
 
(3.1-11)
 
The pressure drop ΔP is also the hydrodynamic resistance offered by the microchannel 
to the fluid front. For design purposes, one can make use of passive geometries to gain 
control over a fluid following in a microfluidic channel. This way of passive fluid control 
is easy to implement and can be done using microstructuring processes [117, 118].  
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Valves and Phaseguides 
Valving is a method used to control the motion of liquid in a microfluidic system. 
Valving can be done by various means and one of the simplest ways is by means of 
geometric structures. This can be achieved by changing the channel geometry such as 
reducing its width using a restriction and then adding an expansion or opening abruptly. 
Thus, the expansion after the restriction will force the approaching liquid meniscus to 
change its shape ultimately requiring a larger pressure to overcome the geometry. The 
meniscus is thus pinned to the channel before the valve opening and will not move 
forward [61-63, 131-133]. 
Phaseguides are also based on the same meniscus pinning effects. They can be 
used to guide the meniscus front during filling of a microfluidic chamber. Phaseguides 
are patterned segments of material perpendicular to the direction of liquid flow. They 
protrude into the channel or chamber and thus act as obstacles, walls or barriers to the 
approaching liquid. The liquid upon reaching the strip of material stops and aligns itself 
to the wall. Upon application of a pressure larger than withstood by the phaseguide, the 
liquid flows further [65, 134-136]. The literature thus allows for theoretical calculation of 
burst pressures that can be withstood by geometrical construction for controlling flow 
in the micrometer scale.  
 
Figure 3.1.5 Passive fluid control: A) Side view of a liquid meniscus reaching a passive 
geometry. B) The three-dimensional meniscus is pinned due to a structure in its paths with 
various contact angles. 
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Figure 3.1.6 Meniscus pinning effect in phaseguides A) Side view of  the advancing liquid 
reaching a phaseguide with fixed dimensions and angle to the approaching meniscus front 
B)-C) Top view as the liquid aligns itself along the first phaseguide and is pinned to it 
before crossing it and flowing along the next. 
 
Using these principles one is free to create geometries which serve functions as 
described in the following paragraph. For design purposes one can assume a liquid flow 
in a restriction followed by an expansion where the top and bottom is made up of the 
same material, having a rectangular geometry with height h and width w and having a 
contact angle θ  with a liquid as in Figure 3.1.5 A). The fluid reaches the opening with an 
angles β1, β2, at top and bottom of the expansion and angles α1, α2 with the walls Figure 
3.1.5 B). The fluid thus has to undergo a change of curvature at the point where the 
opening is present. The contact angle at the opening angle seen by the liquid will change 
from being just θ to (θ+β) and (θ+α). The pressure required for the meniscus to move 
forward would be: 
( ) ( ) ( ) ( )   + + + + + + 
= ⋅ + = ⋅ + ⋅    
     
1 2 1 2
1 2
cos θ β cos θ β cos θ α cos θ α1 1
ΔP γ γ γ
R R h w (3.1-12)
 
Where h is the height and w the width of the restriction or barrier and the angles α1, α2, 
β1, β2 are the curvatures of the opening, which cause a change in advancing angle of the 
filling front with the channel walls. These angles could correspond to either draft angles 
incase of injection molded microfluidic structures or added to the design, for fluid 
control. 
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3.2. Magnetic bead technology 
Magnetic micro- and nanoparticles used in various branches of biomedical 
engineering and medicine [137] have been gaining importance in LOC systems. A number 
of advantages make them suitable in this field such as easy manipulation in flowing fluid 
and their small size offering high surface to volume rations.  
The word magnetophoresis was coined to describe the movement and thus isolation 
of magnetic particles from non-magnetic ones. This method has a wide range of 
applications for example in the mineralogical industries for separating ore from bulk, or 
for the precise separation and manipulation of biological samples.  To understand how 
and why magnetic separations work, one has to comprehend what magnetism is and 
what materials exhibit magnetic properties. In this section properties of magnetic 
materials as well as governing forces are presented. 
3.2.1. Magnetism and magnetic materials 
Magnetism or magnetic fields arises from the movement of a charge like current 
flowing in a coil of wire. Certain materials exhibit magnetism or respond to a magnetic 
field even though no current is flowing through them. Magnetism for such materials thus 
originates from the spinning of an electron as well as from the orbital motion of 
electrons around the nucleus. Thus, electrons produce a spin magnetic moment as well 
as an orbital magnetic moment.  
⋅0B = μ H  
(3.2-1) 
Where B is magnetic induction, magnetic flux density or magnetic field (T) often 
illustrated as the concentration of lines of force of a magnet at any point and H is the 
magnetic field strength, magnetic field intensity, or magnetizing force (Am-1) which 
depends on the magnet and µ0 is the permeability of vacuum (4πx10-7 NA-2) [138]. Upon 
placing a material in a magnetic field the orientations of the individual dipole moments 
are changed and the material is magnetized. There exists within the material an inner 
magnetic induction, which is different from the externally applied field and is material 
dependant.  
  The degree of magnetization is therefore specific to the strength of the applied 
field and to the material. In order to establish whether a material is magnetic or not, 
there is a quantity that can describe the material’s magnetic behaviour under an applied 
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field. The quantity is termed magnetic susceptibility χ (Hm-1), and gives the magnetic 
response of a material through the relationship: 
0⋅M = χ H  
(3.2-2) 
 
Where M is the magnetization of the material and H0 is the externally applied magnetic 
field [138] both having the same units (Am-1).  
Another property exhibited by magnetic materials is one of Hysteresis. To 
determine this generally a hysteresis loop is measured by firstly increasing the field 
intensity H from a low to a high value and then decreasing it again. When the magnetic 
flux B is measured in response to the increasing/decreasing field intensity H it’s called a 
B-H curve and similarly when the magnetization M is measured it gives an M-H curve. 
What is observed is that upon decreasing the field intensity H the original curve is not 
retraced Figure 3.2.1 A).  
 
Figure 3.2.1 Schematic representation of magnetic response of various magnetic materials 
where B is the magnetic flux characteristic of the material and H is the applied magnetic 
field A) ferromagnetic materials showing hysteresis b)paramagnetic materials exhibit 
weak attraction whereas C) diamagnetic are weakly repelled and D) superparamagnetic 
materials showing no remanence when magnetic field is zero [139, 140]. 
 
38   3. Theory 
The material thus acquires a magnetic history where the magnetic flux density B 
does not follow its original values on the initial curve. Several cases arise depending 
upon the B-H curve and a few definitions as follows: 
• Curve symmetrical about origin the material is magnetized to saturation 
• The value of field intensity Hc for which flux density B is zero is known as 
coercivity 
• The value of flux density Br for which field intensity is zero is called retentivity or 
remanence magnetization  
Many important material characteristics can be determined from the B-H curve namely 
that of its magnetic permeability µ (Hm-1) and magnetic susceptibility χ.  
The magnetic permeability µ is derived from the B-H curve and is given by the 
ratio of B/H. The magnetic permeability is thus the degree of magnetization a material 
forms within itself when placed in a magnetic field. The relative permeability of a 
material is the ratio of the permeability of a specific medium to the permeability of free 
space, μ0 giving r 0µ = µ µ . Thus, internal induction or magnetic flux density (magnetic 
field lines per area) depends on the relative magnetic permeability μr (dimensionless) 
which is characteristic of the material. 
The magnetic susceptibility χ can also be measured in terms of the magnetic 
permeability of free space µ0 (4πx10-7 NA-2) which being a constant leads to a new 
dimensionless quantity called relative susceptibility (or volume susceptibility) χr given 
by: 
r
0
χ
χ =
µ
 
(3.2-3) 
 
The relative permeability and relative susceptibility are related as follows: 
r rχ = µ -1  
(3.2-4) 
 
Relative susceptibilities can range from 10-5 (very weak)–106(very strong magnetism). 
In some cases, the relative susceptibility is negative. The behaviour of χr leads to various 
types of magnetism. Elements having a large number of unpaired spins generally exhibit 
greater magnetic behaviour. Depending upon their extent of magnetization, materials 
can be classified into the following five categories, Table 3.2.1 [68, 138]. 
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Table 3.2.1 Categories of magnetization given by their relative susceptibilities (adapted 
from [44, 140]). 
Magnetization type Magnetic characteristics Relative magnetic 
susceptibility χr 
Ferromagnetism Atoms have parallel aligned 
magnetic moments  and it 
exhibits the strongest type of 
magnetism 
• Large 1≫rχ  
• Positive 
Example: Ferrum (Fe) 
χr ~ 100,000 
Ferrimagnetism Atoms are aligned anti-
parallel but the resultant 
magnetic moment is not 
completely zero 
• Large 1≫rχ  
• Positive 
Example: Ferrites (α-Fe) 
 χr ~ 1,000 
Antiferromagnetism Atoms are aligned parallel 
and anti-parallel in a regular 
pattern 
• Small 1≪rχ  
• Positive 
Example: Chromium (Cr) 
χr = 3.13x10-4 
Paramagnetism Atoms have randomly 
oriented magnetic moments 
and they are weakly attracted 
by a magnetic field 
• Small 1≪rχ  
• Positive  
Example: Aluminium (Al) 
χr = 2.07x10-5 
Diamagnetism Atoms have no net magnetic 
moment and are weakly 
repelled by a magnetic field 
• Small 1≪rχ  
• Negative  
Example: Gold (Au) 
χr = -3.44x10-5 
 
Materials such as water, proteins, DNA, cells, polymers, wood and glass are 
considered to be weakly diamagnetic or non-magnetic.  Superparamagnetism, another 
class of magnetism has emerged which are magnetized in a magnetic field but they have 
no magnetic memory or no remanence when the magnetic field is zero. Such behaviour 
is exhibited by magnetic particles having a magnetisable core embedded in a polymer or 
silicon dioxide shell [68]. 
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3.2.2. Magnetic Beads 
The demand for nano and micro sized magnetic particles has lead to a number of 
companies and research groups dedicated for their synthesis and properties. The two 
most popular ways of synthesizing magnetic particles are a magnetic core enveloped by 
a polymer shell (particles sizes 5 – 100 nm) or nano crystals (radius < 10 nm) 
distributed in a polymer matrix (particle sizes 300 nm – 10 μm) as in Figure 3.2.2 A). 
The nano crystals are iron oxides like maghemite (Fe2O3) or magnetite (Fe3O4) but they 
are often made from alloys of transition metals (Ni, Fe, Co, Mg or Zn) or rare earth 
materials (NdFeB or SmCo) [141].  
 
Figure 3.2.2 Schematic diagram of A) a magnetic microparticle with either a single 
magnetic core or consisting of many nanoparticles as the core B) Superstructure formed 
upon application of a magnetic field which shows some remanence and the structure is 
retained when the field is removed (Redrawn from [67]) . 
 
The magnetic beads used in this study are the carboxylic acid functionalized 
Dynabeads® MyOne™. Amblard et al. [142] reported the beads were to be paramagnetic. 
Implying that the beads have a magnetic memory, and retain a remnant moment after 
removal of applied field Figure 3.2.2 B). The composition of the MyOne™ beads as per 
manufacturer is 37% ferrites per gram of dry solid, consisting of magnetite (Fe3O4) and 
maghemite (Fe2O3), within a polystyrene matrix. A glycidyl hydrophilic layer is further 
coated onto the beads [143]. The MyOne™ beads were characterized by superconducting 
quantum interference device (SQUID) magnetometry by T.D. Meehan [144] and Table 3.2.2 
lists the various properties as reported by the manufactures and T.D. Meehan. 
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Table 3.2.2 MyOne™ bead properties as reported by references  [143-145]. 
MyOneTM Beads Properties 
Diameter (ϕ) 1.05 µm 
Concentration 10 mg/mL (7-12x109 beads/mL) 
Density (ρ) 1.8 g/cm3 or 1.8 x 103 kg/m3 
Sedimentation  Remain is solution up to  30 min. 
Relative or volume susceptibility 
(χr) 
0.85 (dimensionless) 
Mass susceptibility (χm =χr/ρ) 
Relative permeability [µr= χr + 1)  
4.7x10-4 m3/kg 
1.85 (dimensionless) 
 
3.2.3. Magnetophoretic forces 
The force on magnetic particles placed within a magnetic field depends on the 
volume of the particles (V), the difference between the magnetic susceptibility of the 
particle (χparticle) and the suspending medium (χmedium) and strength of applied magnetic 
field gradient as follows [67, 68]: 
 ∇ ⋅ 
 
imag
0
Δχ
F = V B B
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(3.2-5) 
Where Δχ= χparticle - χmedium and the volume V, for a sphere of radius r is V=
34 πr
3
. Where
∇B=0 the field is homogeneous the translation force on the particle is zero thus the 
particle would be magnetized and a torque would exist but no translation action occurs. 
When a magnetic particle suspended in a fluid is brought into magnetic field by say a 
permanent magnet or electromagnet a number of forces act on it. The magnetic forces to 
transport or hold magnetic beads in a flow and the viscous drag force acting on the bead 
are given as: 
F = -Fmag vis  
(3.2-6) 
Thus, the viscous or drag forces Fvis experience by the beads is related to the flow 
conditions and the size of the bead. 
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The relationship between viscous drag and a suspended particle is given by: 
⋅ ⋅ ⋅ ⋅visF = 6 π η r Δv  
(3.2-7) 
Where Δv is the velocity of the bead with respect to the liquid medium, η is the viscosity 
of the medium and r the radius of the bead. The forces on magnetic particles vary from a 
few pN to a few tens of pN  [67, 68]. 
Mason number 
Magnetic particles upon exposure to a uniform externally applied rotating 
magnetic field assemble into pearl chain microstirrers. The mixing provided by these 
chains has been studied extensively in literature using video microscopy or simulations 
and is affected by a quantity called the Mason number  [146-148]. The research carried out 
by these groups was to produce chaotic mixing in a microfluidic flow regime. The Mason 
number is expressed as the ratio of viscous force to magnetic force and is a 
dimensionless number defined by equation (3.2-8). Upon inserting equation (3.2-1) into 
equation (3.2-8) one gets the final equation (3.2-9): 
0
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(3.2-9) 
 
Where η is the viscosity of the surrounding fluid, ω is the angular velocity of the rotating 
magnetic field, χr the effective dimensionless susceptibility of the beads, H0 the 
externally applied field strength and µ0 the permeability of free space equal to 4πx10-7 
NA-2. 
At higher frequencies the rotating chain structures length decrease as the hydrodynamic 
viscous forces dominate. According to these reports three regimes can be described 
based on the calculated Mason’s number as: 
• Lower Mason number (Ma≤0.001): Single chains with a phase lag. 
• Intermediate Mason number (0.001<Ma<0.01): Disassociation and re-association 
with the increasing number of chains. 
• Higher Mason number (Ma≥0.01): Single chain with an oscillatory motion 
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3.3. Immunoassay concepts  
Developed in the early 1960s, an immunoassay is an analytical method harnessing 
the ability of certain proteins or oligonucleotides to specifically bind with high affinity to 
an analyte of interest. Though there are a number of such proteins available naturally 
like hormone receptors, antibodies offer various advantages making them a popular 
choice. Some of their advantages are listed as follows: 
• Stable, soluble and abundant 
• Straightforward to manufacture  and immobilize 
• Available with single binding (monoclonal) or multiple binding (polyclonal) 
receptors 
• Apart from bivalent, Immunoglobulin G (IgG), and polyvalent, Immunoglobulin M 
(IgM), monovalent fragments also available 
• Ability to bind natural and man-made chemicals, bimolecular, cells and viruses 
• High specificity and binding constants between an antibody and its target 
Analytical methods employing antibodies and antigen binding are referred to as 
immunoassays[149, 150]. 
3.3.1. Immunometric assay design 
Assays where reagents used in stoichiometric excess are known as 
immunometric or reagent excess assays. The immunometric assay design is one of the 
simplest ways to conduct any assay. It starts with an antibody specific to the antigen of 
interest, being immobilized to a solid substrate (test tube, petri dish, microwell). Then 
the sample containing the targeted antigen is added to the solid substrate permitting its 
capture by the antibody. For the final signal generation phase, another labeled antibody 
specific to the target is added. After washing away the excess unbound label, the signal is 
measured and its level is proportional to the concentration of the target bound.  As the 
capture and detection antibodies form a sandwich around the target, this immunometric 
assay is also called a sandwich immunoassay. There are various other formats available 
for designing an assay depending upon the end application. For example, if the method 
of detection is fluorometry a fluorescent label is employed for the signal generation. An 
illustration of the protocol used during a sandwich immunoassay is given in Figure 3.3.1. 
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Figure 3.3.1 Two-site immunometric assay (sandwich assay) where antibody coated solid 
phase is incubated with a sample A) after a certain period of time unbound analyte is 
washed away B) after which a labeling step for the signal generation take place C) and 
after excess label is washed away D) the read-out is made (Redrawn from [150]). 
 
3.3.2. Kinetics of antibody-antigen interactions 
Bonds are based on electrostatic forces and range from weak Van der Waals 
forces to strong covalent bonds. The binding reaction between an antibody and antigen 
is reversible and depends upon the goodness of the fit between the molecules 
themselves as well as their total contact area [151, 152]. To achieve equilibrium the 
reaction can take anything between a few seconds to many hours depending upon the 
assay design. Factors such as pH and ionic strength of reagents, temperature and even 
the choice of the solid substrate play an important role. 
 The Law of Mass Action can be used to describe antibody-antigen binding as follows: 
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Where [Ag] is the antigen concentration, [Ab] the antibody concentration, Ƙa is the 
rate of association, Ƙb the rate of disassociation and [Ag-Ab] is the bound antigen-
antibody complex. The equilibrium constant Keq is between the ratio rate of association 
and the rate of dissociation. The kinetics of binding is hence defined by two rate 
constants rather than one, which should be well understood in order to design an assay. 
It is also important to remember that equation (3.3-1) is based on a number of 
assumptions as follows: 
• The antigen is homogeneous and is composed of one species 
• The antibody is also homogeneous 
• The antigen has one binding site (epitope) 
• The antibody has one binding site (paratope) recognizing one epitope with one 
affinity 
• Binding is uniform without any allosteric effects meaning binding of antibody 
does not influence further binding sites 
• The reaction reaches equilibrium 
• There is no non-specific binding to the container 
Detection sensitivities can be improved by increasing the ratio between bound and un-
bound antigen thus from equation (3.3-1) one gets: 
[ ]
[ ] [ ] ⋅ eq
Ag - Ab
= Ab K
Ag
 
(3.3-2) 
 
Thus, either increasing the equilibrium constant or the amount of antibody 
concentration can influence the amount of antigen bound and the amount free in 
solution.  
The equilibrium constant depends upon the bound strength expressed by: 
( )
⋅
eq
ΔG
ln K = -
R T
 
(3.3-3) 
 
Where ln is the natural logarithm, ΔG is the change in free energy, R is the universal gas 
constant (8.314472 JK-1mol-1) and T is the absolute temperature (310 K at 37°C). 
Reactions occur spontaneously if the free energy is negative.  
Table 3.3.1 gives an overview of the free energy changes for various equilibrium 
constants showing as the equilibrium constant increase the free energy becomes 
lower[152]. 
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Table 3.3.1 Equilibrium constants (Keq) and their corresponding free energy changes (ΔG) 
at 37°C f [152]. 
Keq (L/mol) ΔG (kJ/mol) 
105 -40 
106 -46 
107 -52 
108 -58 
109 -64 
1010 -70 
 
3.3.3. Assay sensitivity 
The sensitivity of an assay is given by the probability of a non-zero result. The 
question then is at what concentration one would be able to say with certainty that the 
sample is not actually zero, thus determines the final sensitivity.  
For this, the zero standards, blank or negative control (without analyte) is measured 
repeatedly and the limit of sensitivity is calculated as: 
⋅Limit of detection (LOD)= Blank +3 (Standard deviation of blank)  
(3.3-4) 
 
This statistical way to determine the limit of detection (LOD) is termed analytical 
sensitivity.  
The concentration at which quantitative results can be reported with certainty is termed 
the limit of quantification (LOQ) given by: 
⋅Limit of quantification (LOQ)=Blank+10 (Standard deviation of blank)  
(3.3-5) 
 
Thus, the blank or negative control influences the ultimately detection limits reached 
in an assay. The detection limits are very often not measured but rather calculated after 
the empirically data measured is fitted with the help of a mathematical model [150, 153]. 
One typical mathematical model used for fitting data obtained during the measurement 
of a analyte concentration curve is the five parameter logistic model. It is a nonlinear 
regression model and can be used to predict the probability of occurrence of a 
concentration by fitting the measured data to a logistic curve [154]. 
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Figure 3.3.2 Anatomy of the five parameter logistic model for a dose-response curve. 
 
The measured data and hence, curve can be modeled using commercially available 
software and the data is fitted according to the function given below: 
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(3.3-6) 
 
Where A is the lower asymptote or the estimated response at zero concentration, B is 
the upper asymptote or the estimated response at infinite concentration, C is the mid-
range concentration, D is the slope at the inflection point (Hill's slope), and parameter E 
is a compensation factor due to the asymmetric behavior of the curve and adjusts it. 
When E=1 we have a symmetrical curve around inflection point and results in a four 
parameters logistic equation (Figure 3.3.2). In order to determine the final LOD of an 
assay it is often not feasible to measure at that concentration. The modeled curve thus 
gives a prediction of the estimated sensitivity and can be obtained by inserting equation 
(3.3-4) or in case of limit of quantification equation (3.3-5) into the inverse equation 
given below: 
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1
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(3.3-7) 
 
Where A is again the lower asymptote and B is the upper asymptote, C is the mid-range 
concentration, D is the hill’s slope at the inflection point and E is a compensation factor 
due to the asymmetric behavior of the curve. 
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3.4. Fluorescence spectroscopy 
The use of fluorescence in biological sciences is diverse owning to the availability of 
a number of fluorescence emitting substances (fluorophores or fluorescent dyes) and 
their detection techniques. Apart from their availability, fluorescence methods are 
highly sensitive. They are used in immunoassays as part of a labeling procedure, which 
allows the measurement of a target analyte at various concentrations. The usual read-
out system is optical making use of optics combined with electronics for quantifying the 
resulting fluorescence intensity.  
3.4.1. Fluorescence and fluorophores 
Fluorescence is the consequence of a three-phase process that occurs in 
fluorophores or fluorescent dyes normally aromatic molecules.  The three phases can be 
depicted in an electronic-state diagram called Jablonski diagram given in Figure 3.4.1. 
 
Figure 3.4.1  The Jablonski diagram illustrating the phenomena of fluorescence and 
phosphorescence (Redrawn from [155]). 
 
Phase 1 is the excitation of the fluorescence molecules, which acts as an external 
stimulus for the process. The stimulus is supplied in form of a photon and is provided by 
a light source such as laser. This causes the molecule to go into a higher energy level or 
its excited state. The molecule does not remain long at this excited state (typically 1-10 
picoseconds) and undergoes conformational changes. The second phase thus involves 
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the partial dissipation of absorbed energy resulting in the relaxed singlet excited state. 
The third and last phase is when the molecule emits its entire absorbed energy and goes 
back to the ground state.  During the relaxation back to the ground state, it emits a 
photon at a longer wavelength than what it absorbed. This difference in energy or 
wavelength is called the Stokes’s shift. The fluorescence quantum yield (Q) is a ratio of 
the number of fluorescence photons emitted to the number absorbed as in equation 
(3.4-1).  
=
nr
photons emitted
photons absorbed
Γ
Q =
Γ+k
 
(3.4-1) 
Where Γ is the emissive rate of the fluorophore and the rate constants Γ and knr 
depopulate the excited state. The quantum yield is closer to unity when knr < Γ, however 
it’s typically less than unity because of Stoke’s losses. 
Fluorescence life times can be calculated as: 
nr
1
τ =
Γ+k
 
(3.4-2) 
 
The lifetime is thus the average time spent in the excited state and can last about 10 ns 
[155, 156]. 
Fluorescence spectra 
Photobleaching is an important phenomenon, which can occur if a fluorophore is 
irreversibly destroyed during its excited phase, thus ending the normally cyclic 
fluorescence process. Thus, their high sensitivities are because a single fluorophore can 
emit thousands of detectable photons.  
 
Figure 3.4.2 An example fluorescence excitation and emission spectrum for a fluorescent 
dye, Fluorescein, illustrating the Stoke’s shift (Redrawn from [155]). 
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Hence rather than single transitions fluorophores can be excited by a broad energy 
spectra called excitation spectrum and emit in broad emission spectrums. In addition, 
the final intensity of emission is proportional to the amplitude of the excitation 
spectrum at the excitation wavelength as can be seen in Figure 3.4.2. 
3.4.2. Fluorescence techniques 
In order to detect fluorescence signals one has to first generate it by a light source 
acting as a stimulus. Thus, an excitation source such as a laser or an incandescent lamp 
is an essential part of the instrumentation. After the fluorophore undergoes stokes shift 
and emits photons at a higher wavelength some filters are needed, to isolate the emitted 
photons from the excitation photons. Finally a detector, which converts the photons into 
say electronic output, which is then recorded electronically. There are a number of 
fluorescence detection systems each providing different results as given in Table 3.4.1. 
Table 3.4.1Fluorescence instrumentation for different detection modes [156]. 
Instrument Application Example 
Spectrofluorometers  Measures the average signal of 
an entire volume (µL to mL] 
Microplate or 
microwell readers 
Fluorescence microscopes Spatial fluorescence 
measurements (<~0.1 mm 
diameter) 
Fluorescence images of 
cells, DNA, protein etc. 
Fluorescence scanners Two dimensional spatial 
fluorescence measurements 
Electrophoresis gels, 
blots and 
chromatograms 
Flow cytometers Fluorescence measured as 
single events in a flowing 
stream 
Large sample of single 
cell analysis  
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Fluorescence signals  
The fluorescence intensity ultimately measured by a given instrument is based on 
the principles of absorbance given by the Beer-Lambert law. Consider a volume of 
solution with a thickness of dx containing n number of light-absorbing molecules/cm3 as 
in Figure 3.4.3.  
 
Figure 3.4.3 The Beer-Lambert’s law illustrating the principle of light absorption 
(Redrawn from [155]). 
 
The absorbed light intensity dI per thickness dx is proportional to the intensity of the 
incidental light I and to σ and n as follows: 
⋅ ⋅
dI
= -I σ n
dx
 
(3.4-3) 
Where σ (cm2) is the area, over which the light falls in the cross-section. Upon 
rearranging and integrating (3.4-3) and assuming a boundary condition that I=I0 at x=0 
one obtains: 
⋅ ⋅
0Iln = σ n d
I
 
(3.4-4) 
The equation (3.4-4) is the Beer-Lambert’s law for absorption a deviation of which is 
used to define fluorescence intensity as follows: 
⋅ ⋅
0Ilog = ε c d = optical density
I
 
(3.4-5) 
 
Where ε is the molar extinction coefficient (M-1cm-1) and c is the concentration of light 
absorbing molecules is molL-1. Upon combining equations (3.4-4) and (3.4-5) we get: 
⋅
⋅
ε c
σ = 2.303
n
 
(3.4-6) 
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This gives the relationship between the extinction coefficients and the cross-section for 
the light absorbed. Where n=Nc/103 and N is Avogadro’s number one finally gets 
equation (3.4-7). 
⋅
-21 2σ = 3.82×10 ε   (cm )  
(3.4-7) 
 
Another signal often encountered during fluorescence measurements are 
background signals. These can originate either from the sample itself (termed 
autofluorescence) or from unbound or non-specifically bound probes (termed reagent 
background). These signals affect the detection sensitivity and can be minimized in a 
number of ways. For reducing autofluorescence, a filter can be employed to reduce the 
transmission relative to the probe or select probes that absorb and emit at longer 
wavelengths [155, 156].
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4. The Microfluidic Cartridge  
During the last 30 years, biochemical methods employing specific recognition and 
binding of analytes by antibodies, such as sandwich immunoassays, have become 
standard practice. They have also been successfully implemented in commercially 
available diagnostic kits like the home pregnancy test [149]. As the end application of the 
research entailed working with an immunoassay, a closer look was taken into its 
procedure, before designing the microfluidic cartridge.  
Sandwich immunoassays are carried out routinely with the antibody being 
immobilized onto a solid substrate example: Petri dishes and microwells or more 
recently microspheres. A sample with the targeted analyte is pipetted into the wells and 
allowed to bind to its specific antibody present forming complexes during an incubation 
period.  After which the unbound compounds are removed and new reagents are added 
either for washing or labeling purposes.  The final sandwich formed is then detected by 
various optical means such as spectrophotometer, fluorometer or luminometer 
depending upon the label added.  
In the presented thesis, magnetic beads were chosen as the solid substrate for the 
immobilization of antibodies for the assay for reasons explained earlier. The choice of 
this solid phase thus influenced the design and features of the microfluidic cartridge. 
The idea of moving the solid phase, between microfluidic cavities filled with stationary 
fluids needed for the assay, was an attractive one. This enabled pump-less operation, as 
fluids for the assay would be filled into respective chambers and henceforth remain 
stationary as the beads moved. Doing away with bulky pumps was also considered an 
important feature for a POC device as the periphery would be minimized.  
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Thus, the assay procedure using the magnetic beads being moved between 
stationary aqueous buffers formed the basis of the final cartridge design, which needed 
to fulfill the following requirements: 
• Reagent chambers  
• Filling control through phaseguides 
• Aeration and metering using passive stop valves 
• Fully contained disposable cartridge  
• Mass production possibilities 
In this chapter the design of the cartridge based on passive geometries is described 
along with measurements of important design parameters such as the contact angle. 
Simulation of a phaseguide sheds light on the theoretical filling behavior and the 
corresponding pressure profile of the fluid. The performance tests of the final cartridge 
are undertaken to ensure robust filling behavior of the phaseguides and valves. Finally, 
the pressure profile of each chamber is also measured and compared to the simulations. 
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4.1. Contact angle 
Cyclic olefin polymer (COP) was chosen as the material for constructing the 
cartridge, in view of its excellent optical properties exhibiting low autofluorescence 
about two times lower than for polymethyl methacrylate (PMMA) [157] and its 
compatibility with injection molding techniques [158]. This enables cost-effective 
manufacturing – a critical prerequisite for single-use applications, i.e. in vitro 
diagnostics. As the filling behavior of liquid in the cartridge depends largely on its 
material properties, the surface free energy of the polymer was measured. To 
characterize the surface energy of the substrate the Owens, Wendt, Rabel and Kaelble 
method which is a geometric-mean method was used [119, 120, 124, 126]. The goniometer 
used to measure was the EasyDrop DSA16 with the double direct dosing system manual, 
DS4002 from Krüss GmbH, Germany. The experiments were done using the Krüss GmbH 
software DSA II version 2.40 and contact angles were measured using the conic section 
method [122, 123]. For the Owens, Wendt, Rabel and Kaelble method, explained in section 
3.1.1, three test fluids were used with polar and disperse fractions as in Table 4.1.1. 
Table 4.1.1 Surface tensions of the various tests fluids for the Owens-Wendt-Rabel and 
Kaelble method with their respective disperse and polar fractions. 
Test Fluid Surface 
Tension  
mNm-1 (γL) 
Disperse Fraction  
mNm-1(γLD) 
Polar Fraction 
mNm-1(γLP) 
Contact 
angle ° 
(θ) 
Diiodomethane 50.8 50.8 0 36°± 2 
1,5-
Pentanediol 
43.3 27.6 15.7 48° ± 2 
Water 72.8 21.8 51 84°± 6 
 
 The COP substrates were first rinsed with isopropyl alcohol and dried in nitrogen 
flow before the contact angle measurements. Upon the cleansed surface 8µL of the first 
test fluid was pipetted to form a droplet and the contact angle was measured. This was 
repeated 5 times, after which the next test two fluids were measured, accordingly. The 
entire measurement process was also repeated 3 times after which 
P
L
D
L
γ
γ
and 
⋅
L
D
L
γ1+ cosθ
2 γ
 were calculated from values given in Table 4.1.1 and plotted in Figure 
4.1.1 as the x and y axes respectively. 
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  The equation of the straight line gives the free surface energy of the substrate 
where slope of the line ( PS=m γ ) gives the polar part and the constant (
D
S=c γ ) the 
disperse part. Hence, upon substituting the values for the slope and constant as given in 
equation (3.1-8) one gets results as seen in Table 4.1.2. 
Table 4.1.2 Calculated values for the total free surface energy of the COP substrate with 
disperse and polar fractions. 
Surface Tension Result 
Free Surface Energy (γS) 40.85 mNm-1 
Disperse part (γSD) 38.82 mNm-1 
Polar part (γSP) 2.04 mNm-1 
 
In order to design the capillary stop valves and phaseguides, which exploit surface 
tension effects, contact angles of various buffers were also measured on the COP 
substrates. The substrates were prepared as mentioned above using the same contact 
angle goniometer set-up. The angles were measured by the conic section method, which 
 
Figure 4.1.1 Owens-Wendt-Rabel and Kaelble method to determine the disperse and polar 
fractions of the surface tension for COP. Three test liquids with known polar and disperse 
fractions of surface tension are employed and plotting them along x-y gives a straight line. 
The slope of this line returns the polar part and the constant the disperse part for COP. 
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assumes the droplet to be part of a conic section. The approximate contact angles for 
advancing and receding droplets are given in Table 4.1.3. The advancing contact angle 
θadv and receding contact angles θrec were measured as opposed to the static angle at 
equilibrium, as they influence the final filling behavior in the cartridge. 
Table 4.1.3 The measured advancing and receding angles for various buffers on a COP test 
substrate. 
Fluid θadv θrec 
PBS 87°±3 86°±1 
PBSTB 52°±2 51°±4 
LCB 54°±3 26°±2 
SB 59°±3 42°±8 
PBS-Phosphate Buffer Saline, PBSTB-Phosphate Buffer Saline + 0.05% Tween20 and 2% BSA, LCB-Low 
Cross Buffer, SB-Stabilizing Buffer 
4.2. Cartridge design 
The cartridge was designed using CAD software Solidworks® 2010. Prototypes were 
manufactured by micro-milling of blank zeonor® (Zeon Europe GmbH, Germany) cyclic 
olefin polymer (COP) thermoplastic slides. All microstructures were comprised in the 
body of the cartridge. The bottom (cover) of the cartridge consisted of a planar COP foil 
that served as a smooth surface over which magnetic beads could be dragged by the 
external magnetic fields. The cartridge included several chambers, separated by 
capillary stop valves, which could be filled independently with the assay reagents 
through individual inlets. Additionally a waste chamber allowed for the drainage of 
excess fluid (reagent and gas) into it and therefore resulted in a self-contained 
disposable cartridge.  After several design iterations, a master for microinjection 
molding of the final layout was manufactured using a precision milling tools 
(microfluidic ChipShop, Jena, Germany). Devices were micro injection molded from COP 
and sealed using a thin, optically transparent COP foil of 100 µm thickness by 
microfluidic ChipShop (Jena, Germany) from the technical design shown in Figure 4.2.1 
A). Thus, a large number of devices with highly reproducible properties and very smooth 
surface finish were available for running the model assay. 
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Thus, the features that were included fulfilled the following purposes: 
• Large sample chamber for containing more than 20 µL of test solution 
• Smaller reagent chambers with washing buffer and labeling solution for the assay 
• A large waste chamber for containing excess solution thus avoiding any risk of 
contaminations 
• Phaseguides to allowing robust and reproducible filling of each chamber allowing 
a fixed metered volume during each test 
•  Capillary stop valves prevent intermixing of fluids and provided a passage for air 
to escape to the waste and beads to be transported between chamber 
The cartridge is 25.5 mm x 75.5 mm with a thickness of 1.5 mm with all features 
comprised in the top half leaving the sealing foil unstructured. The first sample chamber 
can contain totally 70 µL of sample and beads with the remaining three chambers 
containing 35 µL of reagent each.  The waste chamber is left open to the atmosphere so 
as to allow escape of air during filling and can contain about 100 µL of excess reagents. 
Figure 4.2.1 The microfluidic cartridge A) shows the CAD design of the cartridge 
comprising two parts; a microstructured top half and a planar sealing foil both made of 
COP. B) The various microfluidic components included in the final design and C) the 
injection molded finished product and finally D) the cartridge filled with colored PBS. 
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4.2.1. Fluid control: Phaseguides and Valves 
Phaseguides 
To achieve robust, reproducible and controlled filling, phaseguides were included in 
the design. These act as guiding structures, which direct the direction of fluid flow 
through meniscus pinning effects [65, 134-136] (see section 3.1.2). Chambers could thus be 
filled bubble free by using the sectional filling provided by the phaseguides. The burst 
pressure that they were able to withstand can be calculated using equation (3.1-12) 
assuming the advancing contact angle (θ) of Phosphate Buffer Saline (PBS) on COP to be 
90° and its surface tension (γ) as 71.8 mN/m [159]. The angle α equals 0° as the 
phaseguides are structured perpendicular to the direction of the fluid front and do not 
contain the fluid laterally. The angle β is 85° instead of the expected 90° as a draft angle 
of 5° was included in the design for allowing easier removal of the cartridges after the 
injection molding process. A minimum distance of 1 mm was left between successive 
phaseguides to ensure that the fluid filled each section before encountering the next 
phaseguide. The parameters used for the calculation of the pressure they are able to 
withstand are given in Table 4.2.1. 
Table 4.2.1: Design parameters influencing the effective hydrodynamic resistance offered by 
the phaseguides to the advancing fluid. 
Phaseguides 
 Sample Chamber Reagent Chambers 
Height (h) 300 µm 200 µm 
Width (w) 12-8 mm 8-3 mm 
θ 90° 90° 
α 0° 0° 
β 85° 85° 
γ 71.8 mN/m 71.8 mN/m 
 
 Assuming the parameters given in Table 4.2.1 the burst pressure of the 
phaseguides in the sample and reagent chamber can hence be calculated as 
approximately 240 Pa.  
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Valves 
Capillary stop valves [61-63, 131-133] were included to ensure the exact metering of each 
chamber and also acted as an aeration passage. The sample chamber ended in a capillary 
stop valve connecting it to the waste chamber. The valve was designed to allow excess 
reagent to be drained into the waste chamber. The butterfly stop valves between 
chambers and the sample valve were designed with using the equation (3.1-12). The 
advancing contact angle is 90° for PBS and the draft angle for the valves vertically is 5° 
making β=85°. The valves are structured laterally and the curvature offered to the liquid 
by them is α=5°. 
Table 4.2.2: Design parameters used to calculate the effective hydrodynamic resistance 
offered by the capillary stop valves to the advancing fluid. 
Valves 
 Sample chamber valve Butterfly valves 
Height (h) 200 µm 200 µm 
Width (w) 900 µm 200 µm 
θ 90° 90° 
α 5° 5° 
β 85° 85° 
γ 71.8 mN/m 71.8 mN/m 
 
 Again, assuming the parameters as given in Table 4.2.2 and inserting them into 
equation (3.1-12) the sample valve would theoretically be able to withstand a pressure 
up to 370 Pa and the butterfly valves 420 Pa.  
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4.2.2. Phaseguide: Numerical Simulation  
The pressure profile for the first phaseguide in the sample chamber was 
simulated using multiphysics modeling software package CFD-ACE+ Version 2011.0.60 
(ESI GmbH, France)[160]. For the simulations, a CAD file of the phaseguide was imported 
into the multiphysics software.  The CAD drawing was adapted for the injection molding 
process and hence included a draft angle of 5° in its geometry. The flow module and free 
surfaces module of the software were used with surface tension of 72 mN/m and a 
contact angle of 90° for the liquid being pumped at a velocity of 1 mL/min. The Figure 
4.2.2 A)-E) shows the pressure profile during filling of the sample chamber due to the 
presence of a phaseguide. 
The fluid first flows at a constant pressure until it reaches a phaseguide as seen in 
the pressure profile Figure 4.2.2 A). Upon arriving at the phaseguide it shows a decrease 
in the total pressure Figure 4.2.2 B) where the lowest point is reached as the fluid aligns 
at the corners of the phaseguide and is seen as a dip. The pressure then increases or 
builds ups as the fluid changes its curvature due to the phaseguide Figure 4.2.2 C). The 
pressure begins to fall as the fluid gather enough energy to flow past the phaseguide 
Figure 4.2.2 D) and falls further as the fluid surges forward. After breaking through the 
phaseguide the fluid reaches its previous constant pressure Figure 4.2.2 E). 
  
 
Figure 4.2.2 The fluid fills the chamber at a constant pressure as seen in A) upon reaching 
the phase guide the pressure drops B) with the lowest point seen as a dip, as the fluid aligns 
at the corners. After which the pressure rises until the maximum pressure C) is reached and 
the fluid surges past the phaseguide D) showing a fall in pressure and finally reaches a 
constant pressure as it flows further E). 
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4.3. Performance  
The injection moulded cartridge's performance and filling behaviour was tested 
using coloured PBS solution. Sectional filling provided by the phaseguide due to the 
meniscus filling effects can be seen in Figure 4.3.1 A)-B). This allowed the entire 
chamber to be filled without any bubbles or air pockets and dead volume was avoided. 
Chambers could be filled independently until the valve as seen in Figure 4.3.1 C)-D), 
without any fluid connection to each other. Upon application of a pressure pulse larger 
than the “burst” pressure of the valves, the meniscus broke through as seen in Figure 
4.3.1 E).  
 
 
Figure 4.3.1 A)-B) shows the fluid filling the chamber in sections due to the phase guides, 
thus providing robust bubble-free filling. Valving was achieved by means of geometries as 
seen in C)-E). The fluid flows through the narrow neck until the valve is reached; there it 
comes to a standstill, during which another chamber can be filled with another fluid. The 
chambers remain uncoupled until a pressure higher than the burst pressure that can be 
withstood by the capillary stop valves is applied. The arrow shows the direction of fluid 
flow and the scale bar is 500 µm.  
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4.3.1. Filling Scheme 
The filling scheme is depicted with colored PBS, as in Figure 4.3.2 A)-F) and starts 
with the sample with target analytes and antibody immobilized beads being pipetted 
into the sample chamber total volume being 70 µL. Any excess is reliably drained into 
the provided waste preventing over filling and mixing with reagents in subsequent 
chambers. The remaining chambers, each with a volume of 35 µL, are subsequently filled 
via the in-built inlets.  
 
Figure 4.3.2  The filling scheme starts with A (sample chamber filling) which has a metering valve; 
excess sample is drained into the waste area B). The remaining chambers are then filled and left 
unconnected (C-D). The fluidic connection between chambers is subsequently established by 
applying a pressure pulse to the desired chamber (E, arrow). The completely filled cartridge is seen 
in F. 
 
Once all the chambers were filled, they continued to be separated from each other 
by the air present in the fluid passage as seen in Figure 4.3.2 D), until a connection was 
made as shown in Figure 4.3.2 E). To connect two chambers, a pressure greater than 
that can be withstood by the capillary stop valves separating them was applied. This 
caused the fluid front from the two chambers to meet, thus creating a fluidic passage 
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between the chambers through which the beads were transported. The completely filled 
cartridge, with all chambers interconnected, can be seen in Figure 4.3.2 F). Once filled 
the cartridge was used to conduct a test and no further exchange or replacement of any 
fluid is made. After each test the cartridges are disposed off and a new cartridge was 
used for further experimentation. 
4.3.2. Pressure Profile 
In order to measure the actual pressure withstood by the various microfluidic 
structures such as the stop valves and phaseguides of the cartridge, an in-house 
conceptualized set-up was used. The set-up employed a relative pressure sensor 
HCL12X5D_P1 (Sensortechnics GmbH, Germany) [161]. The sensor was left open to 
atmosphere allowing relative pressure measurement and coupled hydromechanically 
via a T junction to a syringe pump SP210iw (World Precision Instruments, Germany) as 
well as the cartridge. A programme created in LabView 2010 allowed control over the 
syringe pump through a RS232 interface as well as data acquisition from the pressure 
sensor. The pressure sensor was connected to LabView using a data acquisition card (NI 
My-DAQ, National Instruments Germany) with compatible drivers to measure, transfer, 
stored and read data directly on the software. Additionally, in the software algorithm, 
the averaging of several measurements can be implemented for signal processing. For 
the pressure measurement, a sampling rate of 1 kHz was used. This was chosen as  to 
ensure that the sampling rate was more than twice the recording frequency [162]. For 
each 1000 readings the mean value is calculated and written to the data file. The result is 
an average of 1 reading per second, thus the sensor noise is reduced to a minimum.  
As the sensor returned a voltage value and each sensor is different due to 
component tolerances, it had to be characterized first. This can be done by calibrating 
the pressure sensors using a water column. A tube filled with water is connected to the 
sensor when it is at the same level as the sensor, the pressure should be zero Pa, as the 
measured pressure relative to the ambient pressure. However, if the sensor shows a 
bridge output voltage not equal to zero, this means the sensor has a voltage offset. For 
the characterization, the water filled tube is raised in equidistant steps and then the 
corresponding sensor output voltage signal is measured. If the maximum output voltage 
reaches the specified measurement range, the measurement ends. Figure 4.3.3 shows 
the voltage measured at 21 points at different heights form 0-0.2 m in intervals of 0.01m. 
The corresponding pressure was calculated from the height using the formula Phyd =ρgh 
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at a gravitation g of 9.81 m/s2, and the density of water at 25°C taken as 1000 kg/m3. 
Thus, it is possible to use the pressure as a function of the sensor output voltage. In 
order to measure the intermediate pressure values, the measurement curve is 
approximated by a linear regression. 
 
Figure 4.3.3 The calibration curve (grey) returns the sensor specific  pressure values for 
measured voltages.  The calibration shows that the sensor has an offset of  2 mV. 
 
The set-up after calibration was used to fill and record the pressure profile of the 
injection moulded cartridge. The syringe pump was set to a fixed injection rate of 
10µL/min and PBS was infused into the sample chamber as seen in Figure 4.3.4. The 
voltage was measured in V which was first converted to mV. To obtain the 
corresponding pressure the calibration curve is used and the offset 157.4 Pa was added 
to obtain the final range. The measurements were repeated three times and the average 
pressure for the sample chamber inlet is 400 Pa, the phaseguides range from 120 Pa for 
the longer ones to 80 Pa for the shorter one and the valve offers an average pressure of 
350 Pa. 
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Figure 4.3.4 Measured pressure profile for the sample chamber showing various peaks 
caused by the presence of phaseguides and the valve 
 
Similarly the wash and labeling chambers were also measured for their pressure 
profile as seen in Figure 4.3.5. The fluid filled in the middle between phaseguide ② and 
⑤ hence the long interval between the pressure spike measured at the inlet and when it 
broke across a phaseguide ②. The fluid filled the right hand side of the chamber until 
the valve and then broke through to the left side of the same chamber. 
 
Figure 4.3.5 Measured pressure profile for the reagent chamber showing various peaks 
caused by the presence of phaseguides and the valve. The fluid filled the right half of the 
chamber till the valve and then the left half of the chamber was filled. Finally, upon 
continuing pumping of fluid, the front broke through the valve on the left hand side of the 
chamber. 
 
The measurements were also repeated three times and the inlet pressure was recorded 
as 235 Pa, the phaseguides were between 100-40 Pa and the butterfly valves measured 
325 Pa. 
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4.4. Discussion 
In this chapter the requirements, design and performance for a microfluidic 
cartridge for POC application of a sandwich immunoassay was presented. Cyclic olefin 
polymer (COP) was chosen as the material for constructing the cartridge, in view of its 
excellent optical properties exhibiting low autofluorescence and its compatibility with 
injection molding techniques [163]. This enabled cost-effective manufacturing – a critical 
prerequisite for single-use applications, i.e. in vitro diagnostics. 
 As the cartridge design was based on surface tension effects to control fluid using 
special geometries, the surface energy of the substrate and its contact angle with various 
buffers were measured. The Owens, Wendt, Rabel and Kaelble method, which measures 
the polar and disperse fractions of the total surface tension was employed. Since the 
measured polar fraction (measure of hydrophilic character) was low, contributing only 
5% of the total surface tension, the substrate exhibited hydrophobicity. The measured 
values correspond to those from literature [164, 165]. A hydrophobic substrate enables 
control over fluid flow based on geometries and is thus better suited for the proposed 
microfluidic cartridge. However, a disadvantage posed by it would be protein adsorption 
and this would entail loss of analyte to the substrate's surface. One method to counter 
protein adsorption would be to block the surface of the polymeric substrate with 
coatings preventing such interactions. In comparison to other biocompatible 
thermoplastics used in biochips such as polycarbonate (PC) or polymethyl methacrylate 
(PMMA), COP shows slightly higher protein adsorption as measured by Kai, J et. al and 
Roy, S. et al. [166, 167]. Although the cartridge was used without any blocking or pre-
treatment step it should compatible with immunoassays, the reasons have been 
discussed in section 6.5. 
Contact angle measurements are of particular interest when designing a microfluidic 
system based on surface tension based capillary effects. The advancing contact angle 
must be recorded to gain insight into the filling behaviour. The measurements revealed 
that the angles are larger at the advancing liquid-solid interface as compared to the 
receding contact angle; this again confirms that COP has a low surface energy. In 
literature, it is mentioned that the polar fraction of a polymer surface depends on the 
polar fraction of the wetting liquid rather than the polymer itself [168]. The buffers used 
contained PBS as the main ingredient the plus detergents. The small differences between 
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the advancing and receding contact angle indicate the surface is smooth and that the 
polar fraction of the substrate is negligible. Both the advancing and receding edges do 
not come into contact with many polar groups and rearrangement at the interface as 
reported in literature [169] also does not take place. During the initial design OF THE 
cartridge the advancing angle of PBS solution was considered and later the contact 
angles of other assay buffers were also recorded. 
The cartridge chambers were designed to be circular in shape so as to prevent air 
pockets at corners. Additionally phaseguides were included to help align the fluid front 
and allow bubble free filling of the chambers helping metering. Their function in the 
wash and labelling chambers was especially critical during the filling process. Both these 
chambers have one inlet and two outlets and thus phaseguides were needed to ensure 
the entire chamber would be filled before the capillary stop valve was breached. They 
functioned well with all the different buffers needed during the assay. The capillary stop 
valve connecting the sample chamber to the waste was included to allow drainage of 
excess fluid. The valve allows fluid to fill it till the butterfly stop valve providing a 
passage for movement of beads through it and the excess fluid is reliably drained to the 
waste. The valve however offers high hydrodynamic resistance to the fluid front and 
thus a resign with a channel instead of a valve would be more suitable. The butterfly 
stop valves allow for aeration during filling and prevent fluid from the wash and 
labelling chambers to escape when only half full. They also enable the fluid front from 
two chambers to meet when the valve is breached and thus form a passage for the 
transport of beads through them readily. They however can be leaky with time and it is 
important to connect the chambers before they do so. Diffusion can also take place freely 
between the valves which were not designed to prevent it from taking place. The extent 
of diffusion was observed using dyes to colour the various buffers and photographed 
after an hour as seen in Figure 4.4.1. 
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Figure 4.4.1 The figure shows the cartridge filled with various colored buffers  at 0 min A) 
when the connections between chambers are made and B) after standing for 60 min (LCB-
Low Cross Buffer, PBSTB-Phosphate Buffer Saline +Tween 20+BSA, SB-Stabilizing Buffer) 
 
Ink was used to color in the LowCrossBuffer (LCB) and fluorescein for the 
Phosphate Buffer Saline +Tween 20+BSA (PBSTB) whereas the Stabilizing Buffer (SB) 
was not colored. The coloring of the LCB became paler with time as the ink molecules 
settled to the bottom, which was not the case with fluorescein. Although quantification 
was not done, the diffusion-taking place after an hour of standing was minimal between 
the three smaller chambers. The diffusion between the sample chamber and the wash 
chamber was minimal as the length separating the two is the largest. A possible way to 
minimize overall diffusion could be by either increasing the separation between 
chambers or carefully choosing the different buffers. 
The performance of the cartridge was tested using colored PBS to inspect the 
filling behavior as well as observations into included phaseguiding and valving methods. 
Pressure measurements were made in order to characterize its pressure profile during 
filling as well as to measure the hydrodynamic resistance provided by the phaseguides 
and valves. The measured absolute pressure was less than the theoretical calculations 
and the one possible explanation could be that the simulations were done with a faster 
pumping rate of 1 mL/min as opposed to 10 µL/min during the measurements. This was 
necessary in order to reduce the total computational time. However, the pressure profile 
for the first phaseguide in the sample chamber matched the simulation done in the 
numerical modeling software, in its form as seen in Figure 4.4.2. The simulation as well 
as the calculations were in close approximation with each other.  
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Figure 4.4.2  Pressure profile for the first phaseguide in sample chamber in A) numerical 
simulation software in comparison to B) a pressure sensor measurement of the same 
phaseguide. 
 
Presently the cartridge is filled manually by pressure driven flow using a pipette, to 
enable POC application it would be possible to fill using snap on pre-filled reagent 
storage tanks. The reagents for the assay could then be emptied into the chambers using 
a plunger system. The only step required would be the loading of the sample into a well 
and clicking-on the tanks before introduction of the cartridge into the reader system. A 
pressure sensor could be used to monitor the filling process, as each chamber delivers a 
characteristic filling profile.
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5. The Platform  
The microfluidic cartridge was designed for a magnetic bead-based fluorescence 
sandwich immunoassay. The beads constituted both the solid phase for immobilizing 
capture molecules and for the automation of a complete assay procedure on the 
platform. The magnetic actuation was possible via externally-applied magnetic fields 
which manipulated the magnetic beads in the chambers. The actuation schemes were 
used to assemble the beads into pearl chain microstirrers for active incubation and to 
aggregate and to move them through reagent filled chambers. This eliminates the need 
for pumps and tubing or a centrifuge, typically needed for fluid handling and enables 
touch-less operation of the assay within the cartridge. In order to use the beads for 
mixing and transporting between reagent filled chambers an experimental set-up was 
developed. The set-up was developed keeping the requirements for the end platform in 
mind as follows: 
• Automation of assay 
• Compact periphery 
• Pump-less system 
• Panel of analytes 
The first two requirements can be fulfilled by permanent magnets mounted onto 
microcontroller controlled stages allowing automation and a relatively compact 
actuation means. As the beads move rather than the fluid the need for a pump for 
reagent exchange was circumvented. A pump-less system also dismisses the need for 
fluid storage on the system and further decreases peripheral components. Moreover, 
calibration issues and monitoring of the storage tanks is avoided leading to easier 
certification of the final platform. Another important feature which an in vitro 
diagnostics device should offer is testing of a panel of analytes. This can be easily 
realized in the presented platform by simply using antigen specific antibodies coupled to 
the magnetic beads. The cartridge, reagents, platform and measurement method 
remaining unchanged. In this chapter the experimental set-up, magnetic actuation 
schemes for active incubation, transport and the data acquisition are described.  
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5.1. Reconfiguring sandwich assays  
In order to conduct a sandwich immunoassay on the cartridge it was reconfigured to 
a simpler format but with all essential steps as seen in Figure 5.1.1. The assay protocol 
would involve an incubation of sample with antibody coated magnetic beads, followed 
by steps for washing or separation, labeling with fluorescent detection antibody and 
finally fluorescence detection. The assay scheme would start with incubation of the 
sample with beads for a defined period.  
 
Figure 5.1.1 The assay scheme begins when the sample is actively incubated with magnetic 
beads A). It includes a washing step by aggregating the beads and transferring them to the 
next wash chamber B). Upon arrival in the wash chamber the beads are re-dispersed into 
microstirrers C). After a further incubation step with the fluorescent label in the labeling 
chamber D) the sandwich is detected in the last detection chamber through fluorescence 
readout E)(not all steps are shown). 
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This would be followed by accumulation of the beads to a spot and transporting 
them to the washing chamber. The beads would be then re-dispersed and assembled 
into pearl chains by means of a rotating magnetic field. They would be subsequently 
transported, at a fixed velocity, to the labeling chamber and re-assembled into pearl 
chains, after which active incubation could take place again for fixed duration. After the 
incubation with the detection complex, the beads would again be aggregated and 
transported into the final detection chamber. This would serve as a separation step as 
well as ensured a low background during imaging. Finally, the particles, focused into a 
tight aggregate, would be transported into the detection chamber and an image would 
be acquired using a fluorescence camera. Thus, the magnetic actuation is responsible for 
mixing, aggregation, transport and re-dispersion.  
5.2. Experimental set-up 
The experimental set-up for the magnetic actuation as per the assay protocol has 
been depicted in Figure 5.2.1. The hardware consisted of a microscope with camera and 
table, magnets mounted onto stages and a computer for control purposes. The stages 
were installed under the cartridge holder integrated into a standard microscope table 
from Scientifica distributors Multi Channel Systems, Germany. The x travel of 25 mm 
was replaced by a micrometer screw with travel of 50 mm, MW-Import, Germany and 
the y travel was 25 mm. Two neodymium iron boron (NdFeB) rare earth magnets were 
procured for providing the magnetic actuation. One had a cylindrical shape, with a 
diameter of 3 mm and a length of 12 mm (BR Technik Kontor GmbH, Germany) whereas 
the other was conically shaped with a base diameter of 25 mm and a height of 25 mm 
(SuperMagnetMan, USA). A micro motor with 50:1 metal gearbox was bought 
(Modellbau Schönwitz, Germany) on to which the cylindrical magnet was fixed: this 
allowed a rotating magnetic field to be generated. The two magnets, including the motor 
were, and then mounted onto a three axes motorized scanning stage (Standa Ltd., 
Lithuania) as illustrated in Figure 5.2.1. The stages were controlled via an in-house 
developed LabView (National Instruments LabView 2011 SP1, Version 11.0.1, 64-bit) 
user interface, which allowed the actuation of the magnets to the desired positions; it 
was also used to switch the motor on or off. A manual epi-fluorescence microscope 
(Eclipse E600FN, Nikon, Japan) with a peltier cooled CCD camera (DS-Qi1MC, Nikon, 
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Japan) was used to obtain12-bit images. The Nikon imaging software Nis 
Elements(4.00.05, 64-bit Build 787) was used to capture the images which were used 
later to quantify the concentration of the target. Thus, a first proof of principle 
laboratory set-up using magnets mounted on translation stages for manipulating the 
beads was developed. 
 
Figure 5.2.1 Experimental set-up showing the concept for the magnetic actuation and 
image acquisition all being controlled through a LabView user interface.  
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5.3. Magnetic actuation  
The Dynabeads® MyOne™, paramagnetic beads from Life Technologies were 
employed as the solid phase. The 1.05 µm magnetic beads have a core made up of 37% 
iron and a polystyrene coating and are highly monodisperse as seen in Figure 5.3.1. The 
permanent magnets travelled to the centre of each chamber and executed the program 
for either mixing or aggregation as per the assay protocol. 
 
Figure 5.3.1 A) Dynabeads®MyOne™ paramagnetic beads which are highly monodisperse 
and B)are made up of a magnetic core enveloped by a polymer coating. 
 
5.3.1. Mixing and active incubation 
The length of the cylindrical magnet chosen for the mixing process was to ensure an 
even field distribution along the entire length of the largest chamber. The distance 
between the cartridge surface and cylindrical magnet was 4 mm generating a magnetic 
flux density of 20 mT, measured using a teslameter FM 205 with probe AS-NTM from FM 
205 (Projekt Elektronik Mess- und Regelungstechnik GmbH, Germany).  The magnetic 
field lines from the cylinder magnet ( Figure 5.3.2) were modeled in air, using an open 
source software FEMM 4.2 [170]. The cylinder NdFeB magnet was of grade N45 with 
magnetic properties as given in Table 5.3.1 [171] from which the magnetic permeability 
(µr ) was calculated as given in section 3.2.1. 
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Table 5.3.1 Magnetic properties of sintered rare earth permanent magnet (NdFeB N45) 
[171]. 
Magnetic Property  NdFeBr N45  Air 
Remanence  (Br) 1.32 T  - 
Internal coercivity (Hc ) 955 kA/m  - 
µr = µ/µ0 where µ=Br/Hc 1.099  1 
 
 
Figure 5.3.2 Magnetic fields from a cylindrical permanent NdFeB N45 magnets modeled 
with FEMM-freeware. 
 
Mixing was possible by assembling magnetic beads into pearl chain 
microstirrers[66] using a rotating magnetic field, rotating at 3 Hz as shown in Figure 
5.3.3. During active incubation, the microstirrers scanned the entire sample volume 
systematically to extract targets. Such incubation was thought to be quick and efficient 
since interaction between each fraction of the sample and the beads was undertaken.  
The microstirrers traversed the entire chamber to ensure that the complete 
sample volume was methodically scanned for analytes, constituting the active 
incubation step. Active incubation was made possible not only by the microstirrers but 
also by moving the rotating magnet in the x-y plane under the cartridge at a speed of 
100 µm/s. To ensure the beads came into contact with the entire chamber volume 
various translational trajectories were tested as seen in Figure 5.3.4.  
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Figure 5.3.3 Active incubation employing a magnet mounted onto a micro motor causing 
microbeads to assemble into pearl chain microstirrers. 
 
The Mason number for effective mixing was calculated as being 62.7x10-6 using 
equation (3.2-9) assuming the viscosity of the buffers to be similar to that of PBS (main 
constituent) as 0.9 mPas [172]. The parameters used for the calculation are listed in Table 
5.3.2. 
Table 5.3.2 Parameters for calculating the Mason number of effective mixing regimes. 
Parameter Value 
Viscosity (η) 0.9 mPas 
Frequency (f) 3 Hz 
Angular frequency (ω=2πf) 18.85 s-1 
Permeability of vacuum (µ0) 4πx10-7  NA-2 
Relative magnetic susceptibility 
of beads (χr) 
0.85 
Magnetic flux density (B0) 20 mT  
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The Figure 5.3.4 shows microscope images of 106 beads in the sample chamber 
taken in the four sections namely right top (RT), right bottom (RB), left top (LT) and left 
bottom (LB).  
The first set of images that is Figure 5.3.4 A) were captured with the magnet 
rotating at a fixed point in the center of the chamber. They show how a ring of beads is 
formed in the middle of the chamber when the rotating magnet is not translated.  The 
center and outer areas of the chamber are left without beads and thus the entire volume 
could not be scanned.  
The second set of images as seen in Figure 5.3.4 B) shows how the beads behave 
when the rotating magnet is also translated in a "cross" trajectory. Though the beads 
move through a larger area of the sample volume, they were not able to follow the 
movement of the magnet. This occurred as the beads experienced a lag due to viscous 
forces working against them in the fluid. Thus, after several trails it was demonstrated 
that a "star" pathway provided the best mixing as seen in Figure 5.3.4 C). The star path 
ensured that the beads would not lag behind, as the magnet moves from a point more 
distant on the periphery to a point closer to the center of the chamber. This in and out 
movement ensured that at the beads reached every region in the chamber and allowed 
control over a larger number of beads. The cross and start pathways were traversed at a 
speed of 100 µm/sec with the magnet rotating at 3 Hz.  
The different pathways were also tested on the three smaller chambers on the 
cartridge with the cross trajectory yielding the best results and was thus implemented 
for active incubation in them. 
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Figure 5.3.4 Microscope images of microbeads in the sample chamber showing their 
mixing behavior under the influence of a rotating magnetic field A) Stationary in the 
middle B) as the stage moves in a "cross" trajectory and C) during a "star" trajectory.  
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5.3.2. Aggregation and transport  
The magnetic beads were also used to help facilitate exchange of buffer and 
separate the desired targets from other molecules. To accomplish this a focused 
magnetic field, supplied by a conic magnet, was held under the cartridge and moved in 
the x-y direction, in order to form a tight aggregate of magnetic beads as seen in Figure 
5.3.5 A). The aggregate once formed was then slowly dragged over the plane COP foil 
surface at a speed of 100 µm/s to the next chamber.  
 
Figure 5.3.5 Magnetic actuation to transport microbeads between chambers using a 
focused magnetic field to form a compact aggregate and moving horizontally as in A) and 
upon reaching the next chamber moving vertically down B) to re-disperse the microbeads. 
 
Upon arrival in the next chamber, the magnet was moved down away from the 
cartridge surface at a speed of 400 µm/s. This caused the tightly formed aggregate to re-
disperse as seen in Figure 5.3.5 B). The focused magnetic field was also employed during 
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the final detection stage. During detection, the compact aggregated was positioned at a 
pre-defined spot and this saved time needed otherwise in searching for it.  
The conic magnet was placed at a distance of 2 mm beneath the cartridge surface 
supplying a magnetic flux density of nearly 300 mT (Teslameter Projekt Elektronik 
GmbH). The magnetic field lines of the conic magnet were modeled in air, using an open 
source software FEMM 4.2 [170] and the results are shown in Figure 5.3.6 . The cylinder 
NdFeB magnet was of grade N50 with magnetic properties as given in Table 5.3.3 [171] 
from which the magnetic permeability (µr ) was calculated using equation 3.2.1. 
Table 5.3.3 Magnetic properties of sintered rare earth permanent magnet (NdFeB N50) 
[171]. 
Magnetic Property   NdFeBr N50 Air 
Remanence  (Br) 1.41 T - 
Internal coercivity (Hc ) 876 kA/m - 
µr = µ/µ0 where µ=Br/Hc 1.28 1 
 
 
Figure 5.3.6  Magnetic fields from a conic permanent NdFeB N50 magnets modeled with 
FEMM-freeware.  
 
The viscous drag experience by the beads during transport from chamber to 
chamber can be calculated using equation (3.2-7) and taking the viscosity of PBS to be 
0.9 mPas and parameters as in Table 5.3.4 gives approximately 9 pN. As the fluid is 
stationary and only the beads move the difference in velocity (Δv) is 100 µm/s. 
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Table 5.3.4 Parameters for calculating the viscous drag experienced by the beads during 
transportation from one chamber to the next. 
Parameter Value 
Viscosity (η) 0.9 mPas  
Radius of beads (r) 0.525 µm 
Velocity at which beads are 
transported (Δv) 
100 µm/s 
5.4. Image acquisition 
Images (offset and aggregate) captured by the camera (fixed exposure times) were 
processed using the public domain software, ImageJ Version 1.44p (Wayne Rasband, 
National Institute of Mental Health). The exposure time was chosen so as to enable the 
exploitation of the entire dynamic range of the camera, for all protein concentrations 
measured. Assume the fluorescence intensity of captured image yielded gray values I, I0 
and IF at different points (x,y) of the final image. The images needed for the final 
quantification were an offset image IO(x,y), and an image of the aggregate I(x,y). The 
offset thus captured the detection chamber, filled with buffer, correctly positioned to the 
focal length, without influences from the beads or magnet. It was taken prior to 
transporting the aggregate to the detection chamber. The captured images comprises of 
pixels with gray values I ranging from [0, K-1] where say K=212 for a 12-bit image. 
( ) ( ) ( )F OI x, y = I x, y + I x, y  
( ) ( ) ( )O FI x, y = I x, y - I x, y  
(5.4-1) 
 
Where IF(x,y) is the fluorescence purely from the aggregate without offset which we aim 
to is used for the final quantification.  
Using the default function in ImageJ, thresholding was performed for the image I(x,y) as: 
( ) ( )
( )
≥ th
th
Mask I = K -1      for I x, y i
                 =  0          for I x, y < i
 
(5.4-2) 
 
Where ith is the set gray value at which the image is thresholded, 0=black and K-1=white. 
Thus a white and black mask is created, separating the background which is black from 
the object in white.  
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To remove any influences caused by camera noise or diffusion of fluorophore from the 
previous chamber the two images that is the aggregate I(x,y) and the offset IO(x,y) were 
subtracted as follows:  
( ) ( ) ( )
( ) ( ) ( )( )
( )
correct O
F
F
I x, y = I x, y - I x, y
                  = I x, y - I x, y - I x, y
                    = I x, y
 
(5.4-3) 
 
The previously created Mask(x,y) was then subtracted from the corrected image 
Icorrect(x,y), giving a final image which retained the fluorescence intensities of only the 
aggregate without the offset and the background being set to black or zero, as given: 
( ) ( )final correctI = I x, y - Mask x, y  (5.4-4) 
Finally Ifinal was measured using the ImageJ functions provided namely Integrated 
Density and Area%. The ntegrated density returned the sum of all gray values of only the 
selected aggregate corresponding to the fluorescence, as the background is set to zero. 
The area% returned the %area of the image occupied by soley the aggregate from which 
the area of the aggregate in pixel counts could be determined. The signal density was 
thus given by: 
finalSignal Density = I Area of aggregate  (5.4-5) 
This made the signals independent of the area given by the number of beads present 
thus avoiding variations due to possible loss of beads. The same method was used 
analysing both the blank and the various concentrations of positive samples. The 
method used for analyzing the images has been taken partly from literature [173-175] and 
evaluated using MATLAB. 
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5.5. Discussion 
In this chapter a system for comprehensive and robust assay performance in a 
cartridge, without resorting to external peripheral devices for fluidic control was 
demonstrated. The automation of various assay steps all in one cartridge substantially 
simplifies the assay procedure and enhances its robustness.   
This format can also be used to address large sample volumes and is neither limited 
by sample size, as is the case in digital microfluidics [176] assay formats nor makes use of 
an oil phase like in droplet-based [103-105] systems. Through antibody immobilized 
magnetic beads probing of more than a fingerpick of blood (> 20 µL) was made possible 
through a simple actuation method. The actuation parameters such as rotation 
frequency, speed, trajectories and total incubation times can also be adapted to a given 
assay by means of small changes to a software protocol. These features can be exploited 
to further simplify the transfer of additional assay parameters to this system, as it will 
be necessary to ensure that a relevant panel of analytes required for medical diagnostics 
run well on this platform. 
The magnetic beads employed were chosen due to their paramagnetic and 
monodisperse nature. This allowed easy manipulation and all ensured that all beads 
exhibited similar magnetic properties. The implemented mixing schemes were tested to 
make certain every fraction of the sample encountered a binding partner on the beads. 
The mixing due to various schemes was not quantified and the observations made were 
visual interpretations of the particle movements. The mixing was carried out using a 
permanent magnet placed under the cartridge rotating in an x-y plane. This actuation 
causes the magnetic beads dispersed in the sample to be pulled to the bottom of the 
cartridge. The beads therefore do not come into contact with the sample in the entire 
height of the chamber. Thus, the use of electromagnets placed around the cartridge 
causing the microstirrers to be distributed evenly within the entire chamber height may 
ensure improved incubation. At present the microstirrer rotation frequency and 
movement in the x-y plane have been accessed visually. Further measurements to access 
the best rotation frequency and speed of stage movement hence need to be undertaken 
and quantified. The Mason number calculated for the frequencies and buffers used was 
less thaa 0.001 indicating a phase lag, which was also observed during the inspection. As 
inducing chaotic mixing was not a priority, the lag does not pose problems. 
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The assay scheme at present includes a mixing and aggregation step in every 
chamber. Though the mixing of the beads in the sample and labeling chambers is crucial 
to ensure binding further experimentation needs to be undertaken to examine if this is 
necessary in the wash and detection chambers. If the mixing in the mentioned chambers 
is not needed the total assay runtime could be shortened. 
At present, the beads are aggregated to a tight spot during the fluorescence detection 
stage. This would ensure high signal density; also, requiring only one image would be to 
be captured preventing long scanning to get the whole signal. Furthermore, the compact 
size ensured that the aggregate would fit into the focal width of the detector. Thus, no 
signal would be lost due to an area larger than the field of view and scanning for the 
entire signal would be avoided, allowing a single photograph for processing and 
quantification purposes. However as the magnetic beads are opaque a possibility arises 
that they could be preventing signal from lowering lying beads to reach the detector. 
Thus, experimentation to examine other configurations for the final detection aggregate 
should be carried out. One possibility would be to disperse the beads to fit in the field of 
view of the detector and form a more 2D aggregate.  
The image processing is at present carried out using ImageJ analysis software. The 
method for processing the images relies on first an excellent image to start with and 
capture of the background. The entire procedure has however does not run 
automatically and requires a lengthy analysis time. Further image processing software 
such as MATLAB from MathWorks could be used to extract the data for the final 
quantification. 
Our goal was to develop a cartridge-based platform for complex assay formats that 
allowed individual assay steps to be adapted and would provide a sample-to-answer 
system being both quantitative as well as sensitive. Keeping in mind the POCT 
requirements the laboratory set-up developed during the course of this work hence 
served as a test system for the eventual platform. This was thought necessary to test the 
feasibility of the platform for actually automating an entire assay procedure without 
resorting to multiple bulky instrumentation. The resultant platform’s peripheral 
equipment would entail costs for micro stages, magnets and a compact fluorescence 
reader (ESELog, Qiagen) which further supports the system’s suitability for 
implementation in a POC setting. At present, the platform weighs 2.3 kgs with the 
detector and is 10cmx22cmx22cm (plus detector) in dimension as seen in Figure 5.5.1. 
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Figure 5.5.1 A) a CAD rendering and B) final system of the diagnostic platform with the 
fluorescence detector and microstages making for a compact system, Multi Channel 
Systems MCS Gmbh, Reutlingen. 
 
Upgrading this system, in terms of washing buffers and detection media, will involve a 
mechanism in which the chambers start filling as soon as the chip is activated: click-on 
micro reservoirs or tanks will open and mechanical actuators will release their content. 
Since these reservoirs do not need to be stored on the reader, calibration of reagent 
levels is not necessary before each test. 
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6. Interleukin-8 Assay 
Immunoassays come in various formats and designs depending upon the amount 
and nature of the targeted analyte.  As the aim of the presented work was to quantify 
intact biological particles and other cellular structures sensitively, detection of surface 
proteins was necessary. Accordingly, in order to detect proteins a sandwich assay with a 
fluorescence tag was chosen as the analytic method. 
  Proteins are extremely important as they not only form the basic building blocks 
of biological samples but also regulate cellular processes.  They are extremely complex 
and hence challenging to work with. Their molecular architecture is assembled from 20 
amino acids, with the end form depending upon the function. Thus, the tertiary and/or 
quaternary structure governs the proper functioning of a protein. The structure of a 
protein is altered by changes in salt concentration or pH, the presence of oxidants or the 
removal of water, often irreversibly. 
An interleukin-8 assay was selected for the evaluation of the cartridge and 
platform. The assay was developed in the department of Biochemistry, at the NMI using 
the Luminex® 100™ System. Interleukin-8 is involved in intercellular communication 
during an immune reaction and is thus part of the innate immune system response. It is 
a biomarker, which indicates an inflammation in the body. The molecular weight of the 
interleukin-8 dimer is 8 kDa and thus is relatively small protein molecule. 
The assay with its detection limits, as determined from the Luminex® system 
served as the reference and gold standard for comparison of results from the 
microfluidic platform. After testing of various protocols of the interleukin-8 assay on the 
Luminex® system, one was transferred to the cartridge for the first proof of principle 
tests. The assay run on the cartridge was further optimized and the final detection limits 
were determined with the aim to reach similar sensitivities as that of the luminex-based 
assay. Lastly, experiments using human serum were also conducted simulating potential 
clinical samples. 
 The interleukin-8 assay on the cartridge thus served the following purposes: 
• Proof of concept for the cartridge and platform 
• Optimization of test system 
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• Establishing a standard assay protocol and workflow 
• Comparison of detection limits to the reference Luminex® system 
• Example for the detection of other biomarker assays 
• Demonstrating compatibility with clinical samples 
In this chapter the Luminex® system as well as the interleukin-8 assay developed using 
it, is presented. Three protocols are described with varying run times and their 
corresponding detection limits. Then the interleukin-8 assay optimization for the 
microfluidic cartridge is carried out before running tests on the platform. Finally the 
sensitivities reached on the cartridge platform are descried and in the discussion 
compared to commercially available products. 
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6.1.  Luminex bead based assays 
6.1.1. The Luminex technology 
Luminex® 100™ Technology is a platform allowing multiplexing of up to 100 
bioassays in one microwell. The assays are bead based, where the microspheres are 
used as the solid support for the capture of targeted molecules. The polystyrene beads 
are dyed using ratios of two red fluorescent dyes to create 100 differently coded spheres 
as shown in Figure 6.1.1 A). Thus, using these uniquely color-coded addressable beads 
and a laser it is possible to measure multiple analytes in one microwell. For each 
bioassay, corresponding antibodies can be immobilized to the surface of the beads 
through carboxyl groups. The amount of analyte bound is measured through labeling 
with a so-called reporter molecule, which is a green fluorescent dye. 
After the final labeling step, the final complex is injected into the analyzer. The 
analyzer is based on principles of flow cytometry and uses microfluidics to align the 
beads to be read out using a combination of two lasers as in Figure 6.1.1B). The first 
laser illuminates with a wavelength of 635 nm and identifies the bead's color code and 
the second excites at 532 nm to measure the amount of bound analyte on its surface. 
Finally, digital signal processing returns a real-time, quantitative data from the 
measured fluorescence signal for each reaction.  Thus, for each bead set the fluorescence 
intensity is detected and the median fluorescence intensity (MFI) is determined by the 
analyzer. The sensitivity, reliability and accuracy are similar to those observed with 
standard ELISA procedures [177, 178].  
 
Figure 6.1.1 Luminex® 100™ Technology using A) color coded beads and B) flow cytometry 
principles to multiplex assays and quantify data through C) signal processing (images 
adapted from the Luminex Corporation, USA and Biodiagnostics  S.A.Greece). 
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6.2. Interleukin-8 assay design 
The interleukin-8 (IL-8) assay which served as a model assay for the evaluation of 
the cartridge was developed at the NMI [179] on the Luminex® 100™ System (Luminex 
Corporation, Austin, USA). As the aim was to be able to measure the analyte from clinical 
samples on the Luminex system a bead based sandwich assay format was chosen.  It is 
recommended that the capture antibody for a sandwich immunoassay to be monoclonal, 
as they are highly specific recognizing only one epitope on the antigen. The capture 
antibody chosen had an equilibrium constant (Keq) of 7.09x1011 L/mol [180] and a bond 
strength of -70.3 kJ/mol calculated from equation (3.3-3). For the detection antibody 
polyclonal are preferred as they can recognize multiple epitopes on any antigen and are 
cost effective. The antibodies for interleukin-8 were available commercially for ELISA 
formats and thus were purchased for the bead-based assay. After the identification of 
the best matching antibody pair, various concentrations of the capture antibody are 
coupled to 300 µL of Luminex beads and tested.  
The amount of detection antibody used must be selected to obtain the best signal to 
noise ratios with the lowest possible concentration. Cost and the effect on blank signal 
(negative control) are the determining factors for the final concentration chosen. For the 
detection, various formats are available like direct labeling of the detection antibody or 
the use a biotinylated antibody and a fluorescence labeled streptavidin molecule. The 
advantages of using a biotinylated streptavidin labeling method are as follows: 
• The streptavidin-biotin bond is very strong (Keq=1014 to 15 M-1) 
• Each streptavidin can bind 4 biotin molecules leading to signal amplification 
• Labeled streptavidin is very stable to store  
• The labeling process causes less background due to unbound fluorophores 
The testing of different matrices should be done prior to optimization of an assay in 
order to deduce any effects of the matrix on the target. This is important as samples 
collected from humans are not processed in buffer and contain human serum or plasma. 
The buffers for the assay are also just as important as the matrix itself and are used for 
stabilizing, coating, blocking, washing and dilution of sample or antibodies. The correct 
buffer helps preserve the biological activity of adsorbed molecules and prevents 
denaturation, degradation, matrix effects or cross-reactivities. The correct buffer can 
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also help to reduce background, shorten the length of the assay and increase efficiency 
[181].  
6.2.1. The Luminex technology: Interleukin-8 assay 
MagPlex® magnetic microspheres (6.5 µm in diameter) were purchased from 
Luminex Corporation Austin, USA (Bead region 25, Part # MC10025). Briefly, 100 µg/mL 
of capture antibody (Cat.#MAB208, R&D Systems GmbH, Minneapolis, MN, USA) against 
IL-8 was coupled to 300 µL magnetic beads, as per the manufacturer’s protocol [182-186]. 
Recombinant human interleukin (Cat#208-IL-010, R&D Systems GmbH, Minneapolis, 
MN, USA) was prepared by 1:4 serial dilutions for a 8-point standard row. Biotinylated 
detection antibody (Cat#BAF208, R&D Systems GmbH, Minneapolis, MN, USA) diluted to 
a concentration of 0.2 µg/mL and Streptavidin Phycoerythrin (PE) Conjugate 
(Cat#SAPE-001, Moss Inc., Maryland, USA) diluted to 2 µg/mL was used for each test. 
The assay was conducted in a 96 well half-area microplate (Cat#3642, Corning, New 
York, USA). The plate was blocked with a BSA containing buffer for at least 10 min prior 
to introduction of 1000 beads per well. LowCross-Buffer® (Candor Bioscience GmbH, 
Germany) was used as the dilution buffer for the standard protein and the fluorescent 
labeling complex. The wash buffer comprised of PBS with 0.05% Tween 20™. As a 
stabilizing buffer the blocking reagent for ELISA (Stabilizing buffer) (Roche Diagnostics, 
Germany) was used during the final read-out. The assay was conducted in duplicates 
and the final read out was done using the Luminex100 analyzer system using Luminex 
IS2.2 software (Luminex Corporation, Austin, USA). The incubation times for a normal 
IL-8 sandwich-immunoassay run on the Luminex system is 3 ½ hours. As we wanted to 
develop a fast and sensitive POC device, two quicker protocols as given in Table 6.2.1. 
were developed specifically for the evaluation of our system. 
Table 6.2.1 Test protocols for the interleukin-8 assay run on the Luminex100. 
Step/Protocol Normal Short Fast 
Beads with Sample 120 min 120 min 30 min 
Detection Antibody 60 min 60 min (detection 
antibody + Streptavidin-
PE mixed) 
30 min (detection 
antibody + Streptavidin-
PE mixed) 
Streptavidin-PE 30 min 
Washing 2x between 
incubations 
1x between incubations 1x between incubations 
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 The first step included an incubation of beads with the sample allowing them to 
bind. The binding times usually depend upon the molecules themselves and their 
equilibrium constants. After the washing step the sample bound beads are incubated 
with the detection complex. The detection complex consisted of the biotinylated 
detection antibody and streptavidin-PE. They were either incubated in two steps with 
the sample bound beads (normal protocol) or mixed together (short, fast protocol) in 
order to avoid the two separate incubation steps. The final washing step is then followed 
by the fluorescence detection. Figure 6.2.1 shows the calibration curves for the various 
tested protocols. 
 
Figure 6.2.1  The standard curve for the various protocols for the interleukin-8 assay, run 
on the Luminex® 100™ system (n=2). 
 
A five parameter-logistic model [154] with statistical weighting (1/Y) was used to fit the 
curves using OriginPro 9.0, OriginLab as:  
( )
  
     
E-D
B- A
f x = A +
x
1+
C
 
 
(6.2-1) 
 
Where A is the lower asymptote, B is the upper asymptote, C is the mid-range 
concentration, D is the slope at the inflection point (Hill's slope), and parameter E is the 
compensation factor as explained in section 3.3.3. 
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The limit of detection (LOD) and limit of quantification (LOQ) is calculated by first 
inserting the Median Fluorescence Intensity (MFI) of the negative control and its 
standard deviation into equation (3.3-4). The equation then returns a MFI value 
corresponding to the concentration for the LOD and LOQ. To determine the final LOD 
and LOQ in pg/mL, these values must then be inserted into equation (6.2-2) which is the 
inverse of equation (6.2-1), to give the corresponding concentration from the fitted 
curve. 
( ) 
  
     
1
1 -D
EB - A
x = -1 ×C
f(x)- A
 
 
(6.2-2) 
 
Where A is again the lower asymptote and B is the upper asymptote, C is the mid-range 
concentration, D is the hill’s slope at the inflection point and E is a compensation factor 
due to the asymmetric behavior of the curve. The lower asymptote was fixed as the f(x) 
at zero concentration that is at blank or negative control. The calculated parameters for 
the various protocols have been given in Table 6.2.2. 
Table 6.2.2 Results using a five parameter logistic fit for the various standard curves run on 
the Luminex system for the interleukin-8 assay.  
Calculated 
parameters 
Normal protocol Short protocol Fast protocol 
A 26  9  4  
B 25298.0 ± 748.9 24753.9 ± 123.7 36566.1 ± 16610.1 
C 696.9 ± 106.6 1702.3 ± 24.7 6914.6 ± 2785.1 
D 0.65 ± 0.04 0.76 ± 0.006 0.49 ± 0.14 
E 1.7 ± 0.16 1.5 ± 0.018 2.5 ± 0.98 
Limit of 
Detection 
0.26 pg/mL 0.52 pg/mL 3.33 pg/mL 
Limit of 
Quantification 
0.79 pg/mL 1.53 pg/mL 9.18 pg/mL 
Dynamic Range 2.4-625 pg/mL 2.4-2500 pg/mL 2.4-2500 pg/mL 
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6.3. Interleukin
The trials conducted on the Luminex system used as the reference method gave the 
detection limits to be achieved on the cartridge platform. In order to transfer the assay 
onto the cartridge for the proof of
required the shortest run times. This would imply that the results would not be as 
sensitive as the normal protocol but valuable time 
achieve detention limits of 3.33 p
cartridge was conducted using Dynabeads
contained a higher iron content (37%) than the 
also changed for the assay on cartridge
coatings of the beads and the polymer cartridge showed lower autofluorescence values.
6.3.1. Preparation of assay reagents
Dynabeads® MyOne™ with carboxylic acid functionalized surface were obtained 
from Life Technologies. The carboxylic groups bind protein covalently through amide 
binding  with primary amines
functionality of the beads was given as 0.6 mmol/g with the 
10 mg/mL (7-12 x 109 beads
coupled to the 1.05 µm beads as specified by the manufacturer’s protocol
activation through ethyl dimethyaminoproply 
protein is required per mg beads. The 
bead surface are quick to hydrolyze. This hydrolization enables the primary amine 
group of the antibody to bind
Figure 6.3.1 Coupling chemistry of capture antibody to the MyOne™ magnetic spheres
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g/mL on the cartridge-based test. The assay on the 
® rather than the MagPlex® as the beads 
MagPlex® (2-4%). The fluorophore was 
 to the deep red region where the polymer 
 
 as depicted in Figure 6.3.1. The active chemical
initial concentration 
/mL). Monoclonal mouse-anti-human IL-8 antibody was 
carbodiimide (EDC), where 50 µg of 
activated carboxylic acid groups present on the 
 the carboxylic acid groups.  
-8 Assay 
for, as it 
 the goal was to 
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The beads were coupled with capture antibody and then stored in PBS with 0.1% 
Tween 20™ and 0.1% BSA, with the final concentration containing approximately 1x1010 
beads/mL. Correspondence with the manufactures provided information that 20 µg/mL 
of antibody usually binds to the substrate. Thus, the amount of antibody (molecular 
weight 150 kDa or 150000 g/mol) per beads can be calculated as follows: 
-10
c
Molar concentration Ab(in 1mL) = × volume
mol.wt.
0.02 g / L
                                                               = ×0.01 L = 1.33×10 moles
150000 g / mole
 
 The Avogadro’s constant being 6.02x1023 mole-1, the number of antibodies in 1 mL is 
their molar concentration multiplied by the Avogadro’s constant gives 8x1013 antibodies 
per mL. Thus, the amount of antibody per beads, assuming the concentration of beads to 
be 1x1010 /mL is: 
13
10
8×10 per mL
Antibodies(Ab) per bead = = 8000 Ab per bead
1x10 beads per mL
 
Lyophilized standard protein IL-8 (Recombinant Human CXCL8/IL-8; R&D 
Systems GmbH, Minneapolis, MN, USA) was aliquoted into 20 µL aliquots to a 
concentration of 10 µg/mL and frozen as specified by manufacturers. Fresh aliquots 
were thawed, diluted to achieve the required concentration and used immediately for 
each experiment. Biotinylated polyclonal goat-anti-human IL-8 served as the detection 
antibody (Human CXCL8/IL-8 Biotinylated Affinity Purified PAb, Goat IgG; R&D Systems 
GmbH, Minneapolis, MN, USA) and was aliquoted to 20 µL aliquots and frozen, at a 
concentration of 0.1 mg/mL in 50% glycerin.  
The assay in the cartridge was conducted using a Streptavidin-Dylight649 (S-Dy) 
complex instead of the Streptavidin-PE used during the assay development on 
Luminex100.  Fluorescence measurements were hence done in the deep red region of 
the visible spectrum, with excitation peak at 652 nm and emission at 670 nm. The deep 
red region ensured minimized autofluorescence from polymer shell of the magnetic 
beads and COP. The Figure 6.3.2 shows the autofluorescence values contributed by 
various parts of the set-up such as the camera, the lamp, magnet, chip, buffer and finally 
the beads for the two different fluorophores considered.  The R-Phycoerythrin is a red-
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fluorescent, multi-subunit protein having an excitation wavelength of 480, 545, 565 nm 
and emission wavelength of 578 nm.  
 
 Figure 6.3.2 Shows the  maximum grey values of the autofluorescence measured for 
various components making up the final image captured the camera offset is 123 (n=3). 
 
Streptavidin labeled with Dylight649, at a concentration of 0.5 mg/mL, was 
purchased from Biolegend, UK. The various buffers for diluting and washing were as 
mentioned in the section 6.2. 
6.3.2. Assay scheme on cartridge 
Antibody functionalized beads and standard IL-8 protein were diluted in 
LowCross-Buffer® to achieve a fixed bead count and protein concentration, respectively. 
The amount of MyOne™ 1.05 µm beads per test was chosen as 105. This bead count was 
chosen, as the aggregate formed could easily pass through the valves and when 
assembled into microstirrers they were well dispersed within the chamber volume. The 
beads and sample were then filled into the sample chamber with a final volume of 70µL. 
About 35 µL of PBS with 0.05% Tween20 and 2% BSA were pipetted into the wash 
chamber. The biotinylated detection antibody was diluted to a final concentration of 2 
µg/mL and the S-Dy to 4 µg/mL. They were then mixed together (15 µL of each plus 5µL 
buffer) to form the detection complex and immediately filled into the labeling chamber, 
as seen in Figure 6.3.3. The last chamber was filled with 35 µL of stabilizing buffer. 
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Figure 6.3.3 The microfluidic cartridge with chambers filled with various reagents for 
running a fluorescence based sandwich immunoassay for interleukin-8. 
 
The assay scheme started with incubation of the sample with beads for 30 
minutes, (see Figure 5.1.1) followed by accumulation of the beads to a spot and 
transporting them to the washing chamber. The beads were then re-dispersed and re-
assembled into pearl chains by means of the magnetic field rotating at 3 Hz at a velocity 
of 0.2 mm/s. They were subsequently transported at a velocity of 0.1 mm/s to the 
labeling chamber and re-assembled into pearl chains, after which active incubation took 
place again for 30 minutes.  
  After the incubation with the detection complex the beads were again aggregated 
and transported into the final detection chamber. This served as a separation step as 
well as ensured a low background during fluorescence imaging. These short incubation 
times, already tested with the Luminex System, were chosen to get a fast and simple 
protocol for testing a first proof of concept on the cartridge.  
An image of the detection chamber offset (cartridge filled with buffer at the final 
detection position) was captured (exposure time 400ms) prior to transportation of the 
aggregate. Finally, the particles, focused into a tight aggregate, were transported into the 
detection chamber and another image was acquired (exposure time 400ms) using the 
same fluorescence camera.  
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6.4. Results: interleukin-8 assay on cartridge 
6.4.1. Standard curve in buffer 
The interleukin-8 assay was run on the cartridge and was diluted in buffer.  The 
assay on the cartridge was carried out in triplicates and an eight-point standard curve 
was produced.  
 
Figure 6.4.1 The standard curve for interleukin-8 assay run on the cartridge in buffer (n=3). 
 
The sensitivities reached with the presented platform are comparable with the same 
assay run on the Luminex® 100™ system. The dynamic range at present lies between 50-
5000 pg/mL and the coefficient of variance for each concentration is between 3%-18 % 
when measured in buffer. A five parameter-logistic model with statistical weighting 
(1/Y) and the lower asymptote fixed at the blank or negative control value was used to 
fit the curves using OriginPro 9.0, OriginLab Corporation, USA as given in equation 
(6.2-1). To calculate the limit of detection and quantification the equation (3.3-4) was 
used. Results are given in Table 6.4.1 and then the final concentration was determined 
from the regression curve using the inverse equation (6.2-2).  
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Table 6.4.1 Results using a five parameter logistic fit for the standard curve measured in 
buffer run on the cartridge for the interleukin-8 assay. 
Calculated parameters Values 
A 22.5 ± 0 
B 14303.4 ± 2.7E-157 
C 486.1 ± 6.5E+45 
D 0.27598 ± 0 
E 6.6 ± 3.2E-152 
Limit of Detection 17.3 pg/mL 
Limit of Quantification 45.6 pg/mL 
Dynamic Range 50-5000 pg/mL 
 
6.4.2. Standard curve with serum 
The standard curve was also measured using buffer spiked with 10% by volume 
human serum (Figure 6.3.3). The assay on the cartridge was carried out in triplicates 
and a seven-point standard dilution curve was measured.  
 
Figure 6.4.2 The standard curve for interleukin-8 assay run on the cartridge with spiked 
with 10% human serum (n=3). 
 
For the standard curve spiked with serum the coefficient of variance is between 
0.3%-15% for concentrations between 5 pg/mL-5000 pg/mL. Again, a five parameter-
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logistic model with statistical weighting (1/Y) and fixed lower asymptote was used to fit 
the curves using OriginPro 9.0 as given in equation (6.2-1).  
The limit of detection (LOD) and limit of quantification (LOQ) is calculated by first 
inserting the Median Fluorescence Intensity (MFI) of the negative control and its 
standard deviation into equation (3.3-4). The equation then returns an MFI value 
corresponding to the concentration for the LOD and LOQ. To determine the final LOD 
and LOQ in pg/mL, these values must then be inserted into equation (6.2-2) which is the 
inverse of equation (6.2-1) to give the corresponding concentration from the fitted 
curve. The results are given in Table 6.4.2. 
Table 6.4.2 Results using a five parameter logistic fit for the standard curve spiked with 
10% human serum and run on the cartridge for the interleukin-8 assay. 
Calculated parameters Values 
A 29.9 ± 0 
B 1844.1 ± 4.2E-157 
C 5639.3 ± 1E+46 
D 7.4 ± 0 
E 0.12 ± 5E-152 
Limit of Detection 1.5 pg/mL 
Limit of Quantification 6.9 pg/mL 
Dynamic Range 5-5000 pg/m 
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6.5. Discussion 
In this chapter, an interleukin-8 assay was developed and optimized for the 
evaluation of the cartridge with platform. The interleukin-8 assay was selected as it was 
developed using the Luminex® 100™ Technology and thus a comparison of the 
developed system to the state of the art was possible.  
The normal run time from the interleukin-8 assay on the Luminex system is 3 ½ 
hours and included separate incubation steps, with first the biotinylated detection 
antibody and then with the fluorescently labeled streptavidin molecules. However, two 
faster protocols were tested where the biotinylated detection antibody and the 
fluorescently labeled streptavidin were mixed together for the labeling step.  
The short protocol as given in Table 6.2.1 produced similar results as the normal 
protocol and thus the mixing of the detection complex was acceptable. 
The fast protocol lasting 60 minutes was tested in for variations as follows: 
• Beads+ sample: 40 minutes; Detection complex: 20 minutes 
• Beads+ sample: 20 minutes; Detection complex: 40 minutes 
• Beads+ sample: 30 minutes; Detection complex: 30 minutes 
The 30 minutes for both incubation steps resulted in the best results and was hence 
applied on the cartridge. 
The tests on the cartridge, however, were carried out using a different fluorophore 
as that tested on the Luminex system. Fluorescence measurements were done in the 
deep red region of the visible spectrum, with excitation peak at 652 nm and emission at 
670 nm. Apart from minimizing autofluorescence, fluorescent dyes emitting in the red 
region tend to be more photostable, thus causing minimal variations in the signal due to 
photobleaching effects. 
The standard curve for interleukin-8 assay run on the cartridge was measured 
between 5-5000 pg/mL. This was chosen as the levels of interleukin-8 in the body 
during inflammation are between 50-1000 pg/mL in case of an acute inflammation [187, 
188]. After initial loading of reagents, the assay was performed without any human 
intervention or need for extra laboratory equipment. This in effect shortened the time 
generally required for the various assay handling steps, equipment operation and the 
preparation. 
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The assay run on the cartridge showed very good reproducibility as data points 
measured on consecutive days and with different aliquots of the standard interleukin-8 
protein, were reproducible. Furthermore, there were very little variations seen in 
results seen from different standard protein product batches. The assay was also run 
with samples spiked with 10% human serum indicating compatibility of the cartridge 
with samples close to real clinical samples. Furthermore, the assay spiked with human 
serum lowered the limit of detection of the assay on the cartridge. This indicates that the 
capture antibody is able to bind interleukin-8 also in the presence of serum proteins.   
All assays were run using commercially available buffers and demonstrated 
compatibility of the cartridge with over the counter assays. The cartridge was used 
without any blocking step even though COP is hydrophobic [166, 167]. As reported in 
literature the use of surfactants, such as Tween20, Tween80, 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulphonate (CHAPS) or BSA can eliminate protein 
adsorption [189-191]. The buffers used for the dilution of standard protein and detection 
complex from Candor Bioscience GmbH is highly suited for reducing background effects 
and serum matrix effects [192, 193]. The buffers for washing contains Tween20 and BSA 
and the stabilizing buffer from Roche GmbH [194] is also contains the above mentioned 
components. Thus, it was inferred that blocking for preventing adsorption of proteins, 
was unnecessary as such effects were minimized due to the buffers used. From the 
commercially available diagnostic tests detection of biomarkers for cardiac diseases 
such as cardiac troponin I (molecular weight 23876 Da) is widespread. The detection 
limits reported by some manufactures for their POC troponin I tests are as follows: 
Table 6.5.1 Comparison of sensitivities and result times for commercially available 
diagnostic assays for the detection of cardiac troponin I [35, 195, 196]. 
Diagnostic assay Detection limits Limit of blank Sample to results 
time 
Magnotech™,Philips 30 pg/mL 10 pg/mL 5 minutes 
i-Stat® Analyser (Abbott 
Point of Care) 
80 pg/mL 20 pg/mL 10 minutes 
Cardiac Reader® (Roche 
Diagnostics Ltd.) 
<50 pg/mL <50 pg/mL 12 minutes 
Stratus® CS System 
(Siemens) 
70 pg/mL 30 pg/mL 14 minutes 
Triage® System, Alere Inc. 56 pg/mL 10 pg/mL 15 minutes 
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These tests are based on antibody-antigen binding and match the performance of 
central laboratories. Jiang, H. et al. 2011 [47]has summarized some of the highest 
reported sensitivities for a fluorescence immunoassay run on a microfluidic system. 
with the highest LOD of 300 pM [197] for Staphylococcal enterotoxin B. The sensitivities 
reached for the Interleukin-8 assay in this study is 5.75 pM (45.6 pg/mL) in buffer and 
1.46 pM (1.5 pg/mL) when spiked with 10% human serum. 
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7. Hepatitis A Virus Assay 
Evaluation and optimization of the assay protocol, cartridge and platform was 
undertaken with the interleukin-8 assay as described in chapter 6.  The assay also 
allowed comparison of the microfluidic-based test to the state of the art established 
Luminex® system, which served as a reference. 
For the application of detecting whole biological particles and other cellular 
structures, a model assay for identifying Hepatitis A virus (HAV) was chosen. The goal 
was not just to detect HAV but also to be able to quantify the amount present. Measuring 
the amount of virus or viral load allows the estimation of the severity of a viral infection. 
Viral load measurements are often used during the monitoring of an anti-viral therapy 
to assess the patient’s response, for example in cases of Hepatitis B, C. 
  The HAV model assay was designed to detect a surface protein of the virus and 
thus the complete particles as opposed to either anti-HAV antibody present in patient 
blood or the RNA of the virus. The HAV (diameter 27 nm) is a highly contagious 
picornavirus, which affects the liver causing inflammation. A single stranded Ribonucleic 
acid (RNA) virus, its nucleic acid consists of about 7.5 kb, and is enclosed in a capsid. The 
capsid is composed of repeating protein subunits called capsomers without a lipid 
envelope. The capsid thus consists of four proteins VP1, VP2, VP3 and VP4, each 
repeated several times. For the detection of HAV in this work, an antibody against the 
VP1 protein, which is repeated 60 times, was chosen [198]. Due to this repetition, the 
antibody has more chances of holding onto the virus exploiting the avidity phenomena 
[199]. This results in a higher binding strength due to synergistic effects.  
A commonly used method for measuring viral load in laboratories is the Enzyme-
linked immunosorbent assay (ELISA). The ELISA was hence used as a reference method 
for the cartridge-based assay. Prior to transferring the viral load test onto the cartridge, 
a magnetic bead-based assay was developed in a microplate and tested using a 
Spectrofluorometer. After establishing the spectrofluorometer based bead assay, it was 
run on the microfluidic cartridge platform. Parameters such as incubation time and 
effects of magnetic bead concentration on assay sensitivity were studied, after which the 
final limit of detection for the cartridge was determined.   
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7.1. Hepatitis A assay design 
The task of designing and optimizing a bead based fluorescence sandwich assay, 
which would be transferred and run on the cartridge, included measuring parameters 
such as: 
• Incubation times 
• Incubation at Room temperature versus at 37°C 
• Amount of capture antibody coupled to beads 
• Buffers used for dilution and washing 
• Fluorescence label  
• Concentration of detection antibody  
The assay was optimized using a fluorescence detector for microplates and Mediagnost 
GmbH, Germany, carried out the experimentation.  
7.1.1. ELISA 
Cultivation of viral particles was done using cell culture methods [200], which has 
been established by Mediagnost GmbH. To express the concentration of virus particles 
the term titre or titer is used.  
 
Figure 7.1.1 ELISA test used to determine the viral titre, measuring the absorption signal 
corresponding to the maximum possible sample dilution (source Mediagnost GmbH). Where NC 
stands for Negative Control (without HAV). 
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The testing of a viral titre is carried out by serial dilution to obtain approximate 
quantitative information using an ELISA based method. The analytical procedure 
inherently only evaluates for either a positive (presence of target) or negative (absence 
of target). The titre thus corresponds to the highest dilution factor that still yields a 
positive reading. The viral titre used was 1:800, meaning that the ELISA test (Cat#E12, 
Mediagnost GmbH) employed to measure the presence of the HAV yielded a positive yes, 
for up to a 1:800 serial dilution, as seen in Figure 7.1.1. As the method is only an 
approximation of the viral concentration additional experiments were carried out to 
determine the exact viral load.  
For precise quantification, a highly purified 1:2200 titre was used to measure the 
viral concentration using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
assay. This method yielded 8.5x108  Genomic Equivalents per mL (GE/mL) for a titre of 
1:2200. A genomic equivalent is explained by the theory, which states that each cell of an 
organism has an equivalent complement of genetic information. Meaning if the amount 
of genomic equivalence is measured for a sample, it is proportional to the amount of 
particles in the sample [201, 202]. Thus, a titre of 1:2200 has a concentration of  8.5x108  
HAV particles/mL. Using the rule of three the amount of HAV particles/mL can be 
approximated for a titre of 1:800, the results are shown again in Table 7.1.1.  
8
8 8
2200
⇒
2200 Titre 8.5x10  HAV particles / mL 800
=  X = *10 = 3x10  HAV particles / mL
800 Titre X
 
Table 7.1.1 The approximately calculated HAV particle concentration for a 1:800 titre. 
Titre HAV particles/mL 
2200 8.5x108 
800 3x108 
 
 The viral titre used during the remaining experimentation is henceforth assumed 
to have a concentration of 3x108 HAV particles/mL or 3x105 HAV particles/µL. 
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7.1.2. Bead based assay: microplate format 
The bead based HAV assay was designed together with Mediagnost GmbH and 
the following presented experiments were conducted in their laboratories. The assay 
was performed in a microwell format with readout using a Spectrofluorometer. The 
magnetic beads used were the Dynabeads® MyOne™ with carboxylic acid functionalized 
surface, from Life Technologies. The capture antibody used was the monoclonal anti-
HAV, clone 7E7 IgG2a (mAb7E7) (Cat# M40, Mediagnost GmbH) and was coupled to the 
surfaces as described in section 6.3.1 and as per the manufacturer’s protocol [143]. The 
equilibrium constant (Keq) 6.67x108 L/mol and hence bond strength -52.4 kJ for 
mAb7E7 and the VP1 capsid protein was calculated using equation (3.3-3).  The final 
antibody immobilized bead concentration is 1x1010 Beads/mL.  As the detection 
antibody, the same monoclonal anti-HAV antibody (Cat# M40, Mediagnost GmbH) was 
biotinylated using a biotin concentration of 0.05 mg/mL. The final concentration of the 
biotinylated detection antibody (bio-mAb7E7) was 1.82 mg/mL.  Streptavidin labeled 
with Dylight649 (S-Dy), at a concentration of 0.5 mg/mL, was purchased (Cat.# 405224 
Biolegend, UK). For the dilution curve HAV product no. A30 Lot no. 160793/1 was used 
which had a viral titre of 1:800. The dilution buffer used was LowCross-Buffer® (Candor 
Bioscience GmbH, Germany) and the wash buffer (20 times concentrated) for the HAV 
ELISA test (Mediagnost GmbH) was used after diluting with distilled water.  
The assay was conducted in a standard stripwell microplate (Cat.# 3914, Corning, 
NewYork, USA) black in color with medium binding properties, without any prior 
blocking. The beads were diluted 1:100 and 100 µL was pipetted into each well giving a 
concentration of about 107 beads per well. The 107 beads (radius = 0.5µm, Surface Area 
= 3.14 µm2) were chosen to correspond to the area in a standard microwell (radius = 3.5 
mm, Area=38 mm2) used to conduct the ELISA tests.  
The beads were then incubated with 100 µL of sample (HAV) for 2 hours at 37°C 
and shaken at 400 rpm. After washing, 100 µL of  bio-mAb7E7, diluted to a 
concentration of 10 µg/mL was pipetted into the wells and incubated for 1 hour at 37°C 
and 400 rpm. Following another washing process, a final incubation with 100 µL of S-Dy 
diluted to a concentration of 2.5 µg/mL for 30 minutes at 37°C and 400 rpm was 
undertaken. Between each incubation step the samples were washed six times with the 
ELISA wash buffer, using the ELx405 Select Deep Well Microplate Washer (BioTek, Bad 
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Friedrichshall, Germany) and the beads were held using the 96-well ring magnet (Cat# 
7102216, BioTek, Bad Friedrichshall, Germany).  
For the final readout PBSTB (PBS+2% Tween20+0.5% BSA) was added to each 
well and a fluorescence readout was taken using Synergy 2 Multi-Mode microplate 
reader (BioTek, Bad Friedrichshall, Germany). The measurements were made with the 
gain set to 80, the excitation taking place at 620 nm with emission recorded at 680 nm 
using the Top Filter-based Fluorescence detection mode.  The results were read into the 
Gen5™ Reader Control and Data Analysis Software (BioTek, Bad Friedrichshall, 
Germany).  
The tests were conducted in duplicates from which the mean value was 
calculated, and then the entire process was repeated three times. The final mean of the 
three repetitions for every HAV dilution factor is given in Figure 7.1.2. The limit of 
detection (LOD) (see section 3.3.3) is calculated as: 
LOD=Negative control+3*(Standard deviation of NegativeControl) 
 
Figure 7.1.2 The dilution curve for the bead-based assay conducted in a microplate and a 
Spectrofluorometer (source Mediagnost GmbH).Where NC stands for Negative Control (without 
HAV). 
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7.2. Hepatitis A assay on cartridge 
After implementation of the bead-based assay in a microwell and measurements 
using a Spectrofluorometer the assay was ready to be transferred onto the cartridge. For 
the assay on the cartridge the same reagents were employed however the 
concentrations were altered for the detection complex to obtain the optimal results. 
Magnetic beads coupled with capture antibody against HAV (prepared as in section 
7.1.2) and HAV sample was diluted in LowCross-Buffer® and was then filled into the 
sample chamber to make up a final volume of 70 µL. For the washing buffer 35 µL of 
PBSTB (PBS with 2 % Tween20 and 0.5 % BSA) was used and pipetted into the wash 
chamber. The biotinylated detection antibody (bio-mAb7E7) was diluted to a final 
concentration of 2 µg/mL and the S-Dy to 4 µg/mL. They were then mixed together to 
form the detection complex using 15 µL of each, plus 5 µL of buffer to give a final volume 
of 35 µL. Care was taken to first add the biotinylated detection antibody and then the 
fluorophore to avoid clumping, which cannot be explained as of yet. The detection 
complex was filled in the labeling chamber. The last detection chamber was filled with 
35 µL of  blocking reagent for ELISA (Stabilizing buffer) (Roche Diagnostics, Germany). 
The microfluidic cartridge with the contents of each chamber has been depicted in 
Figure 7.2.1.   
The assay scheme started with incubation of the sample with beads for a fixed period 
of time (see Figure 5.1.1), followed by accumulation of the beads to a spot and transport 
to the wash chamber. The beads were re-dispersed upon arrival in the next chamber and 
assembled into pearl chains. The magnetic field was rotating at 3 Hz and translated at a 
velocity of 0.2 mm/s. The beads were finally transported to the labeling chamber, at a 
velocity of 0.1 mm/s, and re-assembled into pearl chains, followed by active incubation 
for a fixed period. After labeling the beads were aggregated and then moved to the final 
detection chamber, this was a washing as well as a separation step, ensuring a low 
background during imaging. An image of the detection chamber offset (cartridge filled 
with buffer at the final detection position) was captured (exposure time 700 ms) prior to 
transportation of the aggregate. Finally, the beads, focused into a tight aggregate, were 
transported into the detection chamber and another image was acquired (exposure time 
700 ms) using the same fluorescence camera. These images were later imported into 
ImageJ and used for the quantification of the fluorescence intensity measured.  
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Figure 7.2.1 The microfluidic cartridge with chambers filled with various reagents for 
running a fluorescence based sandwich immunoassay for the detection of HAV. 
 
7.2.1. Improving signal to noise  
The bead-based assay in the microplate showed limited sensitivity as compared 
to the ELISA, hence the goal was improving sensitivity in the cartridge-based system. 
The first parameter, which was tested, was the amount of bead employed, to observe 
their effects on the signal. 
The antibody coupled beads, concentration 107 beads/µL, were diluted using 
LowCross®-Buffer, as 1:100, 1:1000 and 1:10,000 to give end concentrations of 105 
beads/µL, 104 beads/µL and 103 beads/µL respectively. For the positive control 10 µL of 
one of bead concentrations were pipetted along with 1 µL HAV (approximately 3x105 
HAV particles) and remaining volume LowCross®-Buffer into the sample chamber. The 
end bead concentration was thus 106, 105 and 104 in the sample chamber. The remaining 
chambers were filled as described in section 0, also seen in Figure 7.2.1. For the negative 
control, no HAV was added to the sample chamber. The remaining chambers were filled 
with all the necessary assay reagents as described above. Thus, the beads were 
incubated with a purely buffer solution during a negative control without any HAV in the 
sample chamber. The incubation time of the beads with the sample in the sample 
chamber was 30 minutes as well as with the detection complex in the labeling chamber.  
Priorly, to check the influence of the bead polymer matrix alone 
(autofluorescence) on the signals 106, 105 and 104 beads were measured in stabilizing 
buffer, which is used in the final detection state. 
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The positive control, negative control and autofluorescence tests were repeated 
three times and the images were captured as described in the beginning of section 0 the 
results are shown in Figure.7.2.2.  
 
Figure.7.2.2 The effect of various bead counts on the signal keeping the HAV concentration 
constant at ≈ 3x105 particles (n=3). 
 
The signal to noise was calculated as given below: 
-1Sf(x, y) = = xy
N
x = S (Signal)
y = N(Noise) 
 
 
(7.2-1) 
Where f(x,y) is signal to noise ratio and x is the signal (positive control) and y is the 
noise (negative control).  
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The standard deviation SDxy was calculated as follows: 
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(7.2-2) 
 
The resulting signal to noise ratio and its standard deviation is shown in Figure 7.2.3 and 
given in Table 7.2.1. 
 
Figure 7.2.3 Signal to noise ratios and standard deviations of tests with various bead 
counts (n=3). 
 
Table 7.2.1 The calculated signal to noise and standard deviation for the various bead 
counts. 
Bead Count 104 105 106 
Signal to Noise 4.49 ±0.56  3.45±0.53 3.86±0.46 
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7.3. Results: Optimization of incubation time  
The binding between antigen-antibody depends upon a number of factors one of 
which being the total time allowed for the reaction to take place. In order to ensure 
maximum binding, various incubation times for the beads with the sample and 
incubation with the fluorescence detection complex were tested. To test the incubation 
times a high and low bead count, 106 and 104 beads per test respectively, was selected. 
The experiments were aimed at determining which bead count and incubation times 
were required for optimal results.  
7.3.1. Calibration of microscope objective 
As the quantification of sample concentration was derived from a captured image 
of the fluorescence intensity emitted, it was crucial to capture all the available 
information. Upon measuring the 106 beads with a 10x objective (CFI Plan Flour 10x, 
Nikon, Japan) an area percent of 15-10% of the total 1280x1024 image format was 
occupied by the beads. Whereas the 104 beads occupied an area of only 0.1-0.5% of the 
total 1280x1024 image. Thus, a larger magnification was required in order to capture all 
the fluorescence intensity emitted by the lower bead count. Accordingly, a 40x (CFI Plan 
Flour 40x, Nikon, Japan) objective was used for acquiring the images of the 104 beads. In 
order to compare the data obtained from the two objectives a calibration was made to 
transform the data captured from the 40x objective to its corresponding value using 
the10x magnification.  
For the calibration a secondary antibody goat anti-mouse IgG DyLight 649 
(Cat.#405312, concentration 0.5 mg/mL, BioLegend, UK) against the mouse IgG 
antibody coated beads was used. The IgG DyLight 649 used was diluted to 2.5 µg/mL 
and incubated with antibody coated beads ,1x1010 beads/mL, and was coupled as per 
manufactures instructions. The beads were diluted and pipetted into a chamber in order 
to obtain a total bead count of 104 beads. Then images were captured with exposure 
times ranging from 10-400 ms in intervals of 20 ms with first the 40x objective and then 
the 10 x objective. The experiment was repeated three times and all images were 
processed using ImageJ. The fluorescence signal per area for all the data points are 
plotted in Figure 7.3.1 with the data from the 40x objective on the x-axis and the data 
from 10x objective on the y axis.  
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Figure 7.3.1 Calibration curve for objective 40x conversion to objective 10 x (n=3). 
 
To convert the data acquired from the 40x objective to the 10 x objective a function was 
approximated by a linear regression. Thus, the equation (7.3-1) was used for further 
data analysis.  
⋅y =(0.9063  ± 0.07) x+ (9.742 ±18.87) 
(7.3-1) 
Where x is the fluorescence signal per area calculated from an image taken by the 40x 
objective and y is the corresponding fluorescence signal per area for the 10x objective. 
7.3.2.  Incubation of sample with beads 
In order to optimize the incubation times between the antigen and antibody 
binding in the sample chamber, four time intervals were tested namely 15, 30, 60 and 
120 minutes. Bead counts of 106 and 104 were employed and for the positive control and 
1 µL HAV (approximately 3x105 HAV particles) was used. The remaining chambers were 
filled as described in section 0 also seen in Figure 7.2.1.  
For the negative control no HAV was added to the sample chamber the remaining 
chamber being filled with all the assay reagents. The incubation time with the 
fluorescence detection complex in the labeling chamber was kept constant at 30 
minutes. Both the positive and negative controls were repeated three times and the 
results for 106 bead counts are shown in Figure 7.3.2 
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Figure 7.3.2 Results for varying incubation times of 106 beads with a fixed concentration of 
HAV at ≈ 3x105 particles (n=3). 
The same tests as above were conducted using a fixed bead count of 104 and a 40x 
objective. Both the positive and negative controls were repeated three times and the 
results converted to 10x magnification using equation (7.3-1) are shown in Figure 7.3.3. 
 
Figure 7.3.3 Results for varying incubation times of 104 beads with a fixed concentration of 
HAV at ≈ 3x105 particles (n=3). 
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7.3.3. Incubation with fluorescence detection complex 
After comparing the incubation times of the sample with the beads, incubation 
with the fluorescence detection complex in the labeling chamber was also tested. Again 
two fixed bead counts 106 and 104 were selected and incubated with 1 µL of HAV 
(approximately 3x105 HAV particles) for 30 minutes (positive control). The negative 
control was conducted without any HAV and again incubation period being fixed at 30 
minutes. The labeling step with the fluorescence detection complex in the labeling 
chamber was then varied between 15 minutes to 60 minutes. Both the positive and 
negative controls were repeated three times and the results for 106 bead counts are 
shown in Figure 7.3.4. 
 
Figure 7.3.4 Results for varying incubation times with the fluorescence detection complex 
for 106 beads and a fixed concentration of HAV≈ 3x105 particles (n=3). 
 
The same tests as described before were conducted using a fixed bead count of 104 and a 
40x objective. Both the positive and negative controls were repeated three times and the 
results were converted to 10x using equation (7.3-1) are shown in Figure 7.3.5. 
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Figure 7.3.5 Results for varying incubation times with the fluorescence detection complex 
for 104 beads and a fixed concentration of HAV ≈ 3x105 particles (n=3). 
7.4. Results: dilution curve hepatitis A assay  
To measure the final sensitivity or LOD for the hepatitis A assay a serial dilution 
curve was tested with again 106 and 104 bead count. The time parameters for incubation 
of sample with antibody coated beads and with the fluorescence detection complex was 
kept fixed at 30 minutes.  
The sample (HAV) was diluted in LowCross®- Buffer and added with the fixed bead 
count to the sample chamber. The wash chamber was filled with PBSTB, the labeling 
chamber with the detection complex and stabilizing buffer was pipetted in the final 
detection chamber.  
For the 106 bead count a 5 point serial dilution curve was possible (Figure 7.4.1) and the 
LOD is calculated as: 
LOD= Negative control+3*(Standard deviation of Negative Control). 
As the negative control returned a large value, further serial dilution would lie under the 
LOD or cut-off and thus was not undertaken. 
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Figure 7.4.1 The standard dilution curve for hepatitis A assay using 106 beads run on the 
cartridge in buffer (n=3). Where NC stands for Negative Control (without HAV). 
The serial dilution curve for the hepatitis A assay in the cartridge was also 
conducted using 104 beads. The incubation times were kept fixed at 30 minutes each for 
both the sample with beads and with the detection complex.  
 
Figure 7.4.2 The standard dilution curve for hepatitis A assay using 104 beads run on the 
cartridge in buffer (n=3). Where NC stands for Negative Control (without HAV). 
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The final images were captured using a 40x magnification objective and were 
converted to a 10x magnification using equation (7.3-1). For the 104 bead count a 6 
point serial dilution curve was possible (Figure 7.4.2) and the LOD is calculated as: 
LOD= Negative control +3*(Standard deviation of NegativeControl). 
The additional dilution was possible as the cut-off for the 104 beads was much lower 
thus decreasing the LOD. 
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7.5. Discussion 
In this chapter the results from a bead-based virus assay for the quantification of 
Hepatitis A which was first developed and subsequently run on the cartridge, are 
presented.  
The reference method for comparison of the cartridge was the ELISA test, which is 
routinely used to determine virus concentrations. Firstly, a bead-based assay was 
developed, optimized and tested on a spectrofluorometer before the transferring assay   
onto the cartridge. The bead-based assay analyzed with a spectrofluorometer resulted in 
four time lower sensitivities than the ELISA with the same number of labor-intensive 
steps involved.  The run time for both assays is 3 ½ hours plus the handling time.  
For improving sensitivities on the cartridge, the first parameter to be optimized was 
the total number of beads used during a test. The results from these experiments, 
though showing very small variations, indicated that lowering the bead number could 
increase the signal to noise ratios, ultimately improving sensitivity. The signal to noise is 
calculated by dividing the fluorescence signal per area of the positive control (with HAV) 
by the negative control (without HAV). The increase in sensitivity upon lowering bead 
counts was expected, as during the measurement of low viral concentrations (104 
particles/mL) higher bead numbers (106) would lead to a less concentrated signal. 
Every bead would not be able to bind a virus particles and the fluorescence signal per 
bead (or area) was hence expected to be lower. On the other hand, upon using lower 
bead counts for example 104 beads the fluorescence signal per bead (or area) would be 
higher as every bead would have a chance to bind at least one virus particle. 
However, observation made during the experiments showed that the fluorescence 
signal per area decreases upon lowering bead numbers.  This can be explained by 
looking into the aggregate structure formed due to the varying bead concentrations. As 
the number of beads decrease, the final aggregate which is detected, has a smaller area 
and a therefore decrease in total fluorescence. Upon comparing the total area for 105 
beads and 104 beads  to 106 beads, all measured by the same objective, one would expect 
the 105 beads to have 10% of 106 beads area and the 104 beads only 1% of the area of 
106 beads. The same would be expected for the total autofluorescence values. However, 
the measured area and autofluorescence as given in Table 7.5.1. shows that the 
fluorescence signal per area decreases upon using lower bead counts.  
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Table 7.5.1 Percentage of area and autofluorescence measured for 105 and 104 beads in 
comparison to 106 beads. 
Bead count Total % area of 106 beads Total % autofluorescence of 106 beads 
105 Beads 7% 3% 
104 Beads 3% 1% 
 
This trend is also seen for both the positive control (with HAV) and negative 
control (without HAV). Thus, the fluorescence per area (Fluorescence signal/area) 
automatically decreases upon using lower bead counts.  
Another reason for the higher fluorescence per area for higher beads counts is 
offered upon observing the packing density of the aggregate. The 106 beads are more 
tightly packed as compared to the 104 beads as seen in Figure 7.5.1 or 105 beads (not 
shown). In Figure 7.5.1 A) and B) the brightness indicates the height, with the lighter 
spots closer to the scanning objective. In A) the image contains many darker regions 
indicating three-dimensional structure with many layers. However, in B) the aggregate 
appears to be equally bright throughout implying a more two-dimensional structure. 
 
Figure 7.5.1 Confocal laser scanning microscope images of the detection aggregate using 
A) 106 and B) 104 beads. 
 
Upon dispersing, the 106 beads additional in solution to create a less densely packed 
aggregate, the autofluorescence of the 106 bead counts could be reduced by 42%, the 
area remaining the same. Thus, the aggregate structure itself influences the final signal. 
  
122   7. Hepatitis A Virus Assay 
A calibration of the objectives used to capture 106 and 104 beads was also 
undertaken (Figure 7.3.1). The aim was to convert the signals values captured by the 
40x objective for the 104 beads, into values that would correspond to images taken from 
the 10x objective. Measurements were done using the same aggregate (104 beads) and 
the two objectives (10x, 40x) with varying exposure times. The systematic error seen in 
the curve occurs due to the prolonged exposure of the fluorophore and is due to 
photobleaching effects. The relationship is however linear and could be used for further 
analysis. 
The next parameter, which was tested, was the effect of incubation times both of 
beads with sample and with detection complex, on assay performance. As antigen-
antibody binding is time dependant, the trials were undertaken to find out the best 
assay run times. For these tests, 106 and 104 beads were chosen to observe the 
differences between incubation times for varying bead numbers. The amount of HAV 
used in all positive controls was approximately 3x105 HAV in the sample chamber 
(volume 70 µL). The results of incubation of the sample with the 106 beads show no 
distinction between samples from 15 minutes to 120 minutes. This indicates that due to 
the large amounts of beads and HAV present, the antibody-antigen binding occurs 
rapidly and equilibrium sets in within 15 minutes.  
For 104 bead counts, however a different trend is seen with the signals at 15 and 30 
minutes being significantly lower than results after a 60 or 120-minute incubation 
period. A gradual equilibrium is thus established around 60 minutes. 
Incubation times with the detection complex were also tested, again using 3x105 
HAV and incubated with either 106 or 104 beads in the sample chamber. The results 
from experiments due to their very small variations indicate that equilibrium for both 
bead counts and the detection complex settles in at around 30 minutes. 
The negative control (without HAV) for all the incubation parameters undertaken 
with the various bead counts resulted in the same fluorescence signal per area. The 
negative controls are thus robust and reliable and the non–specific binding was minimal 
and not effected by variations in the incubation time. The negative controls signals 
comprised of up to 98% autofluorescence originating from the polymer matrix of the 
beads, as well as some non-specific binding.  
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For the final dilution curves, HAV concentration was varied and was tested with 106 
and 104 beads. Incubation times were fixed at 30 minutes for the beads and sample as 
well as with the detection complex, for both the bead counts. The results showed higher 
sensitivities upon decreasing the bead counts from 106 to 104. The improved 
sensitivities for the lower bead counts can be explained upon scrutinizing the 
autofluorescence signals emitted by the polymer coating of the beads themselves. Upon 
observing the values for autofluorescence or background fluorescence measured from 
the beads, one concludes that as the number of beads increases so does, the 
autofluorescence and thus the negative control. Thus, 106 beads have 98% more 
autofluorescence coming solely from the beads. As the LOD calculation is based on the 
negative control, an increase in the autofluorescence leads to higher cut-off values. 
Furthermore, upon decreasing the bead counts the amount of HAV bound per bead is 
less for 106 beads as compared to the 104, solely due to the discrepancies in number. As 
the 106 beads, form a multi-layered aggregate part of the signal may be lost due to the 
opaque nature of the beads. This is not the case for 104 beads where the aggregate is 
more two-dimensional ensuring that enough of the HAV loaded beads are exposed.  
The results from the different methods used to detect Hepatitis A have been 
summarized in Table 7.5.2. 
Table 7.5.2 Summary and comparison of sensitivities achieved through the various methods 
to detect the Hepatitis A concentration. 
 Time 
(min) 
Highest detectable 
dilution 
Detected HAV number 
(particles/µL ) 
ELISA 210 1:800 4 x102  
Beads based assay 210 1:200 15 x102  
Cartridge assay 
106 Beads 
75 1:700 4 x102  
Cartridge assay 
104 Beads 
75 1:14,000 21 
 
The 106 beads resulted in sensitivities similar to the gold standard ELISA test and 
showed a 3.5 improved sensitivity in comparison to the bead-based assay run on a 
Spectrofluorometer. The dilution curve with the 104 beads yielded much higher 
detection sensitivities. The results showed a 17.5 times increase as compared to the 
ELISA test and a 70 times increase as compared to the bead-based assay run on a 
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Spectrofluorometer.  The assay run on the cartridge was conducted in 75 minutes and 
thus was almost 3 times faster the both the ELISA and bead-based assay run on a 
Spectrofluorometer. The amount of HAV detected (2 x104 HAV/mL) falls in the clinically 
relevant range present during the first 70 days of the disease found in patient blood 
samples [203] measured by RT-PCR. 
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8. Conclusion 
8.1. Summary 
Laboratory diagnostics are an essential and indispensible component of modern 
medicine. Large central laboratories have led to vast improvements in health care and 
now play a key role in the diagnosis and monitoring of therapy. However, recent trends 
indicate a rising need for on-site testing, for instance in medical practices, operating 
theatres, outpatient clinics or emergency rooms. Cleverly engineered compact products 
made possible due to advances in nanotechnology, molecular diagnostics, information 
technology and microfluidics, can now meet this need. These portable devices offer 
immediate access to a range of diagnostic parameters and thus help the medical 
caregiver to diagnose a case faster and make timely decisions about  therapy [11]. The 
commercial availability of compact and portable diagnostic devices has led to the 
widespread practice of what is now termed ‘Point-of-Care Testing’ (POCT) [5, 204]. 
Furthermore, combining the inherent features of lab-on-a-chip (LOC) systems and 
analysis techniques such as immunoassays, simple and sensitive diagnostic platforms 
which can be used to obtain results rapidly at the POC locations is possible. 
The aim of this work was to develop a LOC system right from the design, fabrication 
and process integration. The product would need to have a high level of functionality 
that could also be manufactured commercially at high volumes. The microfluidic-based 
platform developed during the legwork of this doctoral thesis was for a potential 
diagnostic tool for the universal implementation of immunoassays. As POCT device 
implies the need for a compact, cheap yet sensitive system, various features were 
incorporated to meet this criteria. One such feature offering a high level of functionality 
and meeting the POCT requirements was the use of magnetic beads with actuation 
scheme. They were employed for mixing, incubation with various assay reagents, sample 
separation and preparation. The design of the cartridge and periphery that followed was 
based on this choice of moving the solid phase and not the liquid. 
The design of the microfluidic polymer cartridge comprises of simple geometries to 
control the fluid providing a cheap and disposable solution. Various chamber for 
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metering the reagents needed during a test, allowed for implementation of even 
complex assay formats requiring more processing steps to be run on the cartridge. 
Valves provided between chambers were designed for the aeration of the chambers, 
fluidic connection between chambers allowing for the free passage of beads and to drain 
any reagent excesses into the waste. An important feature of the cartridge is its 
compatibility with commercially available buffers, even including those containing 
detergents, as well as with human serum. The cartridge with its microfluidic functional 
blocks allowed for robust and reproducible filling crucial for the testing process. The 
manufacturing costs of the cartridge can be estimated at 1-2 € for 10,000 pieces. 
The developed periphery was meant to be compact and easily portable, and hence 
consisted of a few magnets mounted onto micro stages. The stages were controlled 
through a software interface, for manipulation of the magnetic beads. Various magnetic 
actuation schemes were tested and a protocol for the automation of an immunoassay 
was developed. The schemes included actuation in order to achieve i) the most efficient 
incubation of the magnetic beads with the sample and ii) transport of the beads as an 
aggregate to prevent  any losses. The actuation parameters can also be adapted to any 
given assay by means of facile changes to a software protocol. These features can be 
exploited to further simplify the transfer of additional assay parameters to this system. 
During the experimentation period, the developed set-up had bulky stages controlled 
through a LabView program and an epi-fluorescence microscope. This provided the 
functional design for the first prototype, which was extremely compact 
(10cmx22cmx22cm), portable (2.3 kg including detector) and easy to operate. 
Fluorescence was chosen as the read-out method and various fluorophores were tested 
to obtain the highest sensitivities. An analysis method was developed to quantify the 
amount of fluorescence captured from the camera.  
Finally, the platform was tested using two immunoassays: Interleukin-8 biomarker 
assay and Hepatitis A virus assay. The assays were first run on a reference system in 
order to compare the platform with the state of the art devices used in regular assay 
development and testing. 
“Moving the solid phase” is a paradigm that enables comprehensive and robust assay 
performance in a cartridge, without resorting to external peripheral devices for fluidic 
control to run the assay. This substantially simplifies the assay procedure and enhances 
its robustness. 
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The limit of detection for the biomarker assay was 1.49 pg/mL (0,186 pM) and with 
the virus assay 2x04 virus particles/ml were detected successfully. The biomarker assay 
run on the platform was as sensitive as the reference method (Luminex® System) and 
the virus assay showed improved sensitivities in comparison to the employed reference 
(ELISA). With the biomarker assay though the total assay time was not decreased but 
the hands-on time and handling was reduced due to the automatization. The virus assay 
yielded a 17.5 times increase in sensitivity compared to the reference method and was 
three times faster. The hypothesis as stated in the beginning is: 
It is possible by concise manipulation of functionalized particles in a microfluidic cartridge, 
to reach a limit of detection (LOD) similar to that of Polymerase Chain Reaction which is to 
have a sensitivity of <103 Particles/mL hence achieving detection of viral antigens, rare 
cells types and other biological particles in clinical samples. 
Hence, these detection limits were approached and the study ended as of present with a 
sensitivity of 2x104 HAV particles/mL made possible through combining microfluidics 
and the manipulation of antibody functionalized magnetic beads. Moreover, valuable 
insights on how to actually reach the final goal was gained. 
8.2. Outlook 
The described cartridge and platform is intended for immunoassays and thus will be 
used with biological samples. In order to work with real clinical samples it would be 
beneficial to evaluate the system using different matrices such as serum, whole blood, 
etc. Furthermore, as the cartridges were used without any blocking steps it would be 
necessary to monitor any adsorption of proteins taking place with time to see if a 
coating would be necessary or can be avoided due to the short run-time. 
The periphery used for the actuation of the magnetic beads was realized using rare 
earth magnets for mixing and transportation. As the magnets were placed under the 
cartridge, the beads are attracted to the bottom. This implies that during the mixing 
process the beads would be mainly in contact with the fluid at the bottom. 
Experimentation by removing the contents of the chamber after incubation with beads 
to test the amount of analyte remaining would shed more light on whether the 
incubation is sufficient. An improvement on the existing actuation system would be 
128   8. Conclusion 
possible by distributing the magnetic beads in entire height of the chamber thus 
allowing access to the entire sample fluid. Electromagnetic actuation as reported by 
other groups [100] could possibility offer the sought solution.   
The assays themselves can be optimized further and various ways to shorten the 
incubation times must be analyzed. However, the incubation times vary and depend 
largely on the antigen and antibody used. Signal amplification methods using fluorescent 
labels such as quantum dots or using absorption measurements rather than 
fluorescence could bring added sensitivity. 
Another feature to be developed is a method to fill the cartridge automatically using 
click on reservoirs and a plunger like system. The filling of the cartridge could be 
triggered and guided by electrical pulses generated by a pressure sensor incorporated to 
monitor the flow.   
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I  Abbreviations 
Symbols    Expansion     Unit 
χ     Magnetic susceptibility   Hm-1 
χr     Relative magnetic susepti-         
     bility 
ε     Molar extinction coefficient   M-1cm-1 
η     Fluid viscosity    Pa.s or 
            Nm-2s-1 
γ     Surface Tension    Nm-1 
Γ     Emissive rate of a    
     fluorophore 
κa     Rate of association 
κb     Rate of disassociation 
µ     micro      10-6 unit 
µ     Magnetic permeability   Hm-1  
µ0     Permeability of vacuum   4πx10-7  
           NA-2 
µr     Relative magnetic permea-         
     bility 
π     Mathematical constant   3.14159 
ω     Angular frequency    s-1 
 
ρ     Density     Kgm-3 
σ     Volume     cm3 
τ     Time      s 
cxxx   I Abbreviations 
θ     Contact angle     ° 
A     Area      m2 
B     Magnetic flux density   T 
c     Concentration    molL-1 
C     Curvature     m 
g     Acceleration due to    9.8 
     gravity     ms-2 
G or ΔG    Gibb’s free energy    J 
h     Height of channel    m 
H0     Magnetic field strength   Am-1 
Keq     Equilibrium constant   M-1(Lmol-1) 
P     Pressure     Pa (Nm-2) 
R     Universal gas constant   8.314472 
           JK-1mol-1 
T     Temperature     K 
T     Tesla unit of magnetic flux density  NA-1m-1 
w     Width of channel    m 
M     Magnetization    Am-1 
N     Avogadro’s number    6.022x1023 
           mol-1 
v     Velocity     ms-1 
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Abbreviations   Expansion    
BSA     Bovine Serum Albumin 
Cat#     Catalogue number 
CCD     Charge Coupled Device 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulphonate 
COP     Cyclic Olefin Polymer 
DNA     Deoxyribonucleic acid 
EDC     Ethyl Dimethyaminoproply Carboiimide 
ELISA     Enzyme-Linked Immunosorbent Assay 
EMA     European Medicines Agency 
FDA     Food and Drug Administration 
GE     Genomic Equivalent 
I, Icorrect, IF, Ifinal, I0   Gray values of images captured 
IVD     In-Vitro Diagnostics 
LAMP     Loop Mediated isothermal amplification 
LCB     Low Cross Buffer 
LFA     Lateral Flow Assays 
LOC     Lab On a Chip 
LOD     Limit Of Detection 
LOQ     Limit Of Quantification 
MFI     Median Fluorescence Intensity 
NC     Negative Control 
NdFeB     Neodymium Iron Boron 
PBS     Phosphate Buffer Saline 
PBSTB    PBS + Tween®20 + BSA 
PC     Polycarbonate 
cxxxii   I Abbreviations 
PCR     Polymerase Chain Reaction 
PDMS     Polydimethylsiloxane 
PE     Phycoerythrin 
PMMA     Polymethyl Methacrylate 
POC     Point-of-Care 
POCT     Point-of-Care Testing 
RNA     Ribonucleic Acid 
RT-PCR     Reverse Transcriptase-Polymerase Chain Reaction  
SB     Stabilizing Buffer 
S-Dy     Streptavidin Dylight649 
SQUID     Superconducting Quantum Interference Device 
WHO     World Health Organization 
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